activity (no data). Thus, a mixt. of 6.14 g p-ClC6H4NHCH2C6H4OCRMeCO2H-p (I; R = Me) (II) Et ester and N NaOH in 95% EtOH was stirred 50 min at 70? to give 5.6 g II. Also prepd. were I (R = H, Et) and the N-methyl and N-benzyl derivs. of II.

IT **58336-67-7P 58336-68-8P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 58336-67-7 HCAPLUS

CN Propanoic acid, 2-[4-[[(4-chlorophenyl)methylamino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 58336-68-8 HCAPLUS

CN Propanoic acid, 2-[4-[[(4-chlorophenyl)(phenylmethyl)amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



L6 ANSWER 26 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN

Full Text | Citing References

ACCESSION NUMBER:	1976:421078 HCAPLUS
DOCUMENT NUMBER:	85:21078
TITLE:	Azetidinone derivatives
INVENTOR(S):	Kamiya, Takashi; Yoshihisa, Takarazuka; Hashimoto, Masashi; Teraji, Tsutomu; Takaya, Takao; Komori, Tadaaki; Nakaguti, Osamu; Oku, Teruo; Shiokawa, Youichi; et al.
PATENT ASSIGNEE(S):	Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE:	Ger. Offen., 318 pp. CODEN: GWXXBX
DOCUMENT TYPE:	Patent
LANGUAGE:	German
FAMILY ACC. NUM. COUNT:	2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2529941	A1	19760408	DE 1975-2529941	19750704
JP 51125061	A2	19761101	JP 1974-77091	19740704
JP 51125062	A2	19761101	JP 1974-85526	19740724
JP 51125064	A2	19761101	JP 1974-88452	19740731
JP 51075056	A2	19760629	JP 1975-2650	19741223
BE 830934	A1	19760102	BE 1975-157924	19750702
CH 618161	A	19800715	CH 1975-8634	19750702
DK 7503023	A	19760105	DK 1975-3023	19750703
FI 7501949	A	19760105	FI 1975-1949	19750703

NO 7502419	A	19760106	NO 1975-2419		19750703
FR 2278335	A1	19760213	FR 1975-20990		19750703
FR 2278335	B1	19821217			
SE 428799	B	19830725	SE 1975-7683		19750703
SE 428799	C	19831103			
NL 7508008	A	19760106	NL 1975-8008		19750704
AU 7582778	A1	19770106	AU 1975-82778		19750704
ES 439134	A1	19770301	ES 1975-439134		19750704
ZA 7504306	A	19770525	ZA 1975-4306		19750704
GB 1519495	A	19780726	GB 1975-28394		19750704
HU 172476	P	19780928	HU 1975-FU336		19750704
AT 7505170	A	19790715	AT 1975-5170		19750704
AT 355034	B	19800211			
CA 1063108	A1	19790925	CA 1975-230828		19750704
AT 7806099	A	19790915	AT 1978-6099		19780822
AT 7806098	A	19800415	AT 1978-6098		19780822
AT 359514	B	19801110			
SE 7903460	A	19790419	SE 1979-3460		19790419
SE 7903504	A	19790420	SE 1979-3504		19790420
CH 637924	A	19830831	CH 1980-5357		19800711
PRIORITY APPLN. INFO.:			JP 1974-77091	A	19740704
			JP 1974-85526	A	19740724
			JP 1974-88452	A	19740731
			JP 1975-2650	A	19741223
			JP 1974-100159	A	19740830
			JP 1974-101712	A	19740902
			JP 1974-102288	A	19740904
			JP 1974-136561	A	19741126
			JP 1974-138137	A	19741129
			JP 1975-3779	A	19741225
			JP 1975-1272	A	19741228
			JP 1975-16584	A	19750207
			JP 1975-18241	A	19750212
			JP 1974-30356	A	19750312
			JP 1975-30356	A	19750312
			JP 1975-32702	A	19750317
			JP 1975-32703	A	19750317
			JP 1975-33292	A	19750318
			JP 1975-34830	A	19750319
			JP 1975-33821	A	19750320
			JP 1975-33822	A	19750320
			CH 1975-8634	A	19750702
			AT 1975-5170	A	19750704

GI



AB After the antibiotic FR-1923 (obtained from fermentation liquor of

```
=> s beswick, p?/au and harling, j?/au and keanthous, s?/au  and lambert, m?/au and
            57 BESWICK, P?/AU
            65 HARLING, J?/AU
             0 KEANTHOUS, S?/AU
           937 LAMBERT, M?/AU
          1064 PATEL, V?/AU
          2313 SIMPSON, J?/AU
L13          0 BESWICK, P?/AU AND HARLING, J?/AU AND KEANTHOUS, S?/AU  AND
               LAMBERT, M?/AU AND PATEL, V?/AU AND SIMPSON, J?/AU

=>
```

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	DEC 05	CASREACT(R) - Over 10 million reactions available
NEWS 4	DEC 14	2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS 5	DEC 14	2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS 6	DEC 14	CA/CAplus to be enhanced with updated IPC codes
NEWS 7	DEC 21	IPC search and display fields enhanced in CA/CAplus with the IPC reform
NEWS 8	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/ USPAT2
NEWS 9	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 10	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS 11	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS 12	JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS 13	JAN 30	Saved answer limit increased
NEWS 14	JAN 31	Monthly current-awareness alert (SDI) frequency added to TULSA

NEWS EXPRESS JANUARY 03 CURRENT VERSION FOR WINDOWS IS V8.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT http://download.cas.org/express/v8.0-Discover/

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 01:40:31 ON 06 FEB 2006

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 01:40:40 ON 06 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 3 FEB 2006 HIGHEST RN 873528-70-2
DICTIONARY FILE UPDATES: 3 FEB 2006 HIGHEST RN 873528-70-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading structure

L1 STRUCTURE UPLOADED

=> i1
L1 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> d i1
L1 HAS NO ANSWERS
L1 STR



Page 1-A



Page 1-C



Page 1-D



Page 2-C



Page 2-D



Page 3-C

Page 3-D

```
VAR G1=5-10 5-13/7-10 7-13/8-10 8-13
VAR G2=17-16 17-22/18-16 18-22/19-16 19-22
VAR G3=33/24
REP G20=(1-2) 9-2 9-4
NODE ATTRIBUTES:
HCOUNT  IS M1     AT   1
HCOUNT  IS M2     AT   5
HCOUNT  IS M2     AT   6
HCOUNT  IS M2     AT   7
HCOUNT  IS M2     AT  17
NSPEC   IS C      AT   1
NSPEC   IS C      AT   2
NSPEC   IS C      AT   3
NSPEC   IS C      AT   4
NSPEC   IS C      AT   5
NSPEC   IS C      AT   6
NSPEC   IS C      AT   7
NSPEC   IS C      AT   8
NSPEC   IS C      AT   9
NSPEC   IS C      AT  10
NSPEC   IS R      AT  11
NSPEC   IS R      AT  12
NSPEC   IS R      AT  13
NSPEC   IS R      AT  14
NSPEC   IS R      AT  15
NSPEC   IS R      AT  16
NSPEC   IS C      AT  17
NSPEC   IS C      AT  18
NSPEC   IS C      AT  19
NSPEC   IS C      AT  20
NSPEC   IS C      AT  21
NSPEC   IS C      AT  22
NSPEC   IS C      AT  23
NSPEC   IS R      AT  24
NSPEC   IS R      AT  25
NSPEC   IS R      AT  26
```

```
NSPEC   IS R      AT  27
NSPEC   IS R      AT  28
NSPEC   IS R      AT  29
NSPEC   IS C      AT  30
NSPEC   IS C      AT  31
NSPEC   IS C      AT  32
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS  AT   1  2  3  5  6  7  8  9 17 18 19 20 22 23 31 32 33
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC I
NUMBER OF NODES IS  33

STEREO ATTRIBUTES: NONE


=> s l1
SAMPLE SEARCH INITIATED 01:46:30 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    34602 TO ITERATE

  5.8% PROCESSED     2000 ITERATIONS                                0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       680925 TO   703155
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> s l1 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 166.50 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 01:46:34 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   688949 TO ITERATE

 98.8% PROCESSED   680618 ITERATIONS                              186 ANSWERS

100.0% PROCESSED   688949 ITERATIONS                              186 ANSWERS
SEARCH TIME: 00.00.24

L3          186 SEA SSS FUL L1

=> file hcaplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   171.34     171.55

FILE 'HCAPLUS' ENTERED AT 01:47:01 ON 06 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
```

FILE COVERS 1907 - 6 Feb 2006 VOL 144 ISS 7
FILE LAST UPDATED: 5 Feb 2006 (20060205/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 30 L3

=> s l4 and beswick, p?/au
57 BESWICK, P?/AU
L5 1 L4 AND BESWICK, P?/AU

=> d l5, ibib abs hitstr, 1

L5 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2004:2818 HCAPLUS
DOCUMENT NUMBER: 140:59406
TITLE: Preparation of [[[(hetero)arylamino]methyl]phenoxy]acetic acid derivatives as hPPAR activators for treatment of cardiovascular disease and related disorders
INVENTOR(S): **Beswick, Paul John**; Harling, John David; Kleanthous, Savvas; Patel, Vipulkumar Kantibhai; Simpson, Juliet
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 98 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000762	A2	20031231	WO 2003-EP6416	20030618
WO 2004000762	A3	20041014		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2489359	AA	20031231	CA 2003-2489359	20030618
EP 1513795	A2	20050316	EP 2003-738057	20030618
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003011935	A	20050322	BR 2003-11935	20030618

JP 2005534673	T2	20051117	JP 2004-514762		20030618
NO 2004005327	A	20050310	NO 2004-5327		20041203
PRIORITY APPLN. INFO.:			GB 2002-14254	A	20020620
			WO 2003-EP6416	W	20030618

OTHER SOURCE(S): MARPAT 140:59406
GI



AB Title compds. I [wherein R1 and R2 = independently H or alkyl; X = a bond, CH2, or O; R3 and R4 = independently H, alkyl, OCH3, CF3, allyl, or halo; X1 = CH2, SO2, or CO; R5 = alkenyl, alkanoyl, alkylsulfonyl, or (un)substituted alkyl(phenyl); R6 = (un)substituted Ph or 6-membered heteroaryl; or pharmaceutically acceptable salts, solvates, or hydrolyzable esters thereof] were prepd. as human peroxisome proliferator activated receptor (hPPAR) activators. For example, coupling of Et 2-methyl-2-[2-methyl-4-[[[4-(trifluoromethyl)benzyl]amino]methyl]phenoxy]propanoate with 2-bromo-6-[4-(trifluoromethyl)phenyl]pyridine in the presence of Pd(OAc)2, (R)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl, and cesium carbonate in toluene gave the tertiary amine. Sapon. with NaOH in THF provided the acid II. Compds. of the invention showed at least 50% activation of hPPARδ relative to the pos. control at concns. of 10-7 M or less. Thus, I and their pharmaceutical compns. are useful for the treatment of hPPAR mediated conditions, such as dyslipidemia, syndrome X, heart failure, hypercholesterolemia, cardiovascular disease, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidemia, obesity, anorexia bulimia, or anorexia nervosa (no data).

IT **637353-32-3P**, 2-Methyl-2-[2-methyl-4-[[[4-(trifluoromethyl)benzyl][6-[4-(trifluoromethyl)phenyl]pyridin-2-yl]amino]methyl]phenoxy]propanoic acid **637353-33-4P**, 2-[4-[[Butyl[6-[4-(trifluoromethyl)phenyl]pyridin-2-yl]amino]methyl]-2-methylphenoxy]-2-methylpropanoic acid **637353-34-5P**, [4-[[Butyl[6-[4-(trifluoromethyl)phenyl]pyridin-2-yl]amino]methyl]-2-methylphenoxy]acetic acid **637353-35-6P**, [4-[[Butyl[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino]methyl]-2-methylphenoxy]acetic acid **637353-36-7P**, [4-[[(2-Methoxyethyl)[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino]methyl]-2-methylphenoxy]acetic acid **637353-37-8P**, [2-Methyl-4-[[(pentyl)[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino]methyl]phenoxy]acetic acid **637353-38-9P**, [4-[[(2-Cyclopropylethyl)[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino]methyl]-2-methylphenoxy]acetic acid **637353-39-0P**, [2-Methyl-4-[[propyl[4'-(trifluoromethyl)-1,1'-biphenyl-3-

yl]amino]methyl]phenoxy]acetic acid **637353-40-3P**, [2-Methyl-4-[[[2-(methylthio)ethyl][4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino]methyl]phenoxy]acetic acid **637353-41-4P**, [4-[[Butyl[2-methyl-4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino]methyl]-2-methylphenoxy]acetic acid **637353-42-5P**, [4-[[(2-Methoxyethyl)[2-methyl-4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino]methyl]-2-methylphenoxy]acetic acid **637353-43-6P**, [4-[[(Butyryl)[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino]methyl]-2-methylphenoxy]acetic acid **637353-44-7P**, [2-Methyl-4-[[(propylsulfonyl)[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino]methyl]phenoxy]acetic acid **637353-45-8P**, [4-[[Butyl[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino]sulfonyl]-2-methylphenoxy]acetic acid **637353-46-9P**, [2-Methyl-4-[[(pentyl)[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino]sulfonyl]phenoxy]acetic acid **637353-47-0P**, [4-[[(2-Cyclopropylethyl)[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino]sulfonyl]-2-methylphenoxy]acetic acid **637353-48-1P**, [4-[[Butyl[4-[4-(trifluoromethyl)phenyl]pyrimidin-2-yl]amino]methyl]-2-methylphenoxy]acetic acid **637353-49-2P**, [4-[[Butyl[4-(4-chlorophenyl)pyrimidin-2-yl]amino]methyl]-2-methylphenoxy]acetic acid **637353-50-5P**, [4-[[(2-Methoxyethyl)[4-[4-(trifluoromethyl)phenyl]pyrimidin-2-yl]amino]methyl]-2-methylphenoxy]acetic acid **637353-51-6P**, [4-[[[4-(4-Chlorophenyl)pyrimidin-2-yl](2-methoxyethyl)amino]methyl]-2-methylphenoxy]acetic acid **637353-52-7P**, [2-Methyl-4-[[propyl[4-[4-(trifluoromethyl)phenyl]pyrimidin-2-yl]amino]methyl]phenoxy]acetic acid **637353-53-8P**, [4-[[Butyl[6-[4-(trifluoromethyl)phenyl]pyrazin-2-yl]amino]methyl]-2-methylphenoxy]acetic acid **637353-54-9P**, [4-[[Butyl[6-(4-methylphenyl)pyrazin-2-yl]amino]methyl]-2-methylphenoxy]acetic acid **637353-55-0P**, [4-[[(2-Methoxyethyl)[6-[4-(trifluoromethyl)phenyl]pyrazin-2-yl]amino]methyl]-2-methylphenoxy]acetic acid **637353-56-1P**, [4-[[Butyl(2,4'-dimethyl-1,1'-biphenyl-3-yl)amino]methyl]-2-methylphenoxy]acetic acid **637353-57-2P**, [4-[[Butyl(4'-fluoro-2-methyl-1,1'-biphenyl-3-yl)amino]methyl]-2-methylphenoxy]acetic acid **637353-58-3P**, [4-[[Butyl(4'-cyano-2-methyl-1,1'-biphenyl-3-yl)amino]methyl]-2-methylphenoxy]acetic acid **637353-59-4P**, [4-[[Butyl(4'-methoxy-2-methyl-1,1'-biphenyl-3-yl)amino]methyl]-2-methylphenoxy]acetic acid **637353-60-7P**, [4-[[Butyl(4'-chloro-2-methyl-1,1'-biphenyl-3-yl)amino]methyl]-2-methylphenoxy]acetic acid **637353-61-8P**, [4-[[(4'-Chloro-2-methyl-1,1'-biphenyl-3-yl)(2-methoxyethyl)amino]methyl]-2-methylphenoxy]acetic acid **637353-62-9P**, [4-[[(2,4'-Dimethyl-1,1'-biphenyl-3-yl)(2-methoxyethyl)amino]methyl]-2-methylphenoxy]acetic acid **637353-63-0P**, [4-[[(2-Methoxyethyl)(4'-methoxy-2-methyl-1,1'-biphenyl-3-yl)amino]methyl]-2-methylphenoxy]acetic acid **637353-64-1P**, [2-Methyl-4-[[[2-methyl-4'-(trifluoromethyl)-1,1'-biphenyl-3-yl](propyl)amino]methyl]phenoxy]acetic acid **637353-65-2P**, [4-[[(4'-Chloro-2-methyl-1,1'-biphenyl-3-yl)(propyl)amino]methyl]-2-methylphenoxy]acetic acid **637353-66-3P**, [4-[[(2,4'-Dimethyl-1,1'-biphenyl-3-yl)(propyl)amino]methyl]-2-methylphenoxy]acetic acid **637353-67-4P**, [4-[[(4'-Fluoro-2-methyl-1,1'-biphenyl-3-yl)(propyl)amino]methyl]-2-methylphenoxy]acetic acid **637353-68-5P**, [4-[[(4'-Cyano-2-methyl-1,1'-biphenyl-3-yl)(propyl)amino]methyl]-2-methylphenoxy]acetic acid **637353-69-6P**, [4-[[(4'-Methoxy-2-methyl-1,1'-biphenyl-3-yl)(propyl)amino]methyl]-2-methylphenoxy]acetic acid **637353-70-9P**, [4-[[Butyl[5-methyl-6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]amino]methyl]-2-methylphenoxy]acetic acid **637353-71-0P**, [4-[[Butyl[6-(4-methoxyphenyl)-5-methylpyrimidin-4-yl]amino]methyl]-2-methylphenoxy]acetic acid **637353-72-1P**, [4-[[Butyl[5-methyl-6-(4-

methylphenyl)pyrimidin-4-yl]amino]methyl]-2-methylphenoxy]acetic acid **637353-73-2P**, [4-[[Butyl[6-(4-chlorophenyl)-5-methylpyrimidin-4-yl]amino]methyl]-2-methylphenoxy]acetic acid **637353-74-3P**, [4-[[Butyl[6-(4-chlorophenyl)pyrazin-2-yl]amino]methyl]-2-methylphenoxy]acetic acid **637353-75-4P**, [4-[[[6-(4-Chlorophenyl)pyrazin-2-yl][2-(methyloxy)ethyl]amino]methyl]-2-methylphenoxy]acetic acid **637353-76-5P**, [2-Methyl-4-[[propyl[6-[4-(trifluoromethyl)phenyl]pyrazin-2-yl]amino]methyl]phenoxy]acetic acid **637353-77-6P**, [2-Methyl-4-[[[5-methyl-6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl](propyl)amino]methyl]phenoxy]acetic acid **637353-78-7P**, [4-[[[6-(4-Chlorophenyl)-5-methylpyrimidin-4-yl](propyl)amino]methyl]-2-methylphenoxy]acetic acid **637353-79-8P**, [2-Methyl-4-[[[5-methyl-6-(4-methylphenyl)pyrimidin-4-yl](propyl)amino]methyl]phenoxy]acetic acid **637353-80-1P**, [2-Methyl-4-[[[5-methyl-6-[4-(methyloxy)phenyl]pyrimidin-4-yl](propyl)amino]methyl]phenoxy]acetic acid **637353-81-2P**, [4-[[Butyl[6-[4-(trifluoromethyl)phenyl]pyrazin-2-yl]amino]methyl]-2-ethylphenoxy]acetic acid **637353-82-3P**, [2-Ethyl-4-[[(2-methyloxyethyl)[6-[4-(trifluoromethyl)phenyl]pyrazin-2-yl]amino]methyl]phenoxy]acetic acid **637353-83-4P**, [4-[[Butyl[5-methyl-6-(4-methylphenyl)pyrimidin-4-yl]amino]methyl]-2-ethylphenoxy]acetic acid **637353-84-5P**, [4-[[Butyl[2-methyl-4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino]sulfonyl]-2-methylphenoxy]acetic acid **637353-85-6P**, [4-[[Butyl[6-(4-chlorophenyl)-5-methylpyrimidin-4-yl]amino]methyl]-2-ethylphenoxy]acetic acid **637353-86-7P**, [4-[[Butyl[5-methyl-6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]amino]methyl]-2-ethylphenoxy]acetic acid **637353-87-8P**, [2-Ethyl-4-[[[2-(methyloxy)ethyl][4-[4-(trifluoromethyl)phenyl]pyrimidin-2-yl]amino]methyl]phenoxy]acetic acid **637353-88-9P**, [2-Methyl-4-[[(2-propen-1-yl)[6-[4-(trifluoromethyl)phenyl]pyridin-2-yl]amino]methyl]phenoxy]acetic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(hPPAR activator; prepn. of [[[(hetero)arylamino]methyl]phenoxy]acetic acid derivs. as hPPAR activators for treatment of cardiovascular disease and related disorders)

RN 637353-32-3 HCAPLUS
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[[4-(trifluoromethyl)phenyl]methyl][6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 637353-33-4 HCAPLUS

CN Propanoic acid, 2-[4-[[butyl[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]amino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 637353-34-5 HCAPLUS

CN Acetic acid, [4-[[butyl[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-35-6 HCAPLUS

CN Acetic acid, [4-[[butyl[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-36-7 HCAPLUS

CN Acetic acid, [4-[[(2-methoxyethyl)[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-37-8 HCAPLUS

CN Acetic acid, [2-methyl-4-[[pentyl[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 637353-38-9 HCAPLUS
CN Acetic acid, [4-[[(2-cyclopropylethyl)[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-39-0 HCAPLUS
CN Acetic acid, [2-methyl-4-[[propyl[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 637353-40-3 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[2-(methylthio)ethyl][4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 637353-41-4 HCAPLUS
CN Acetic acid, [4-[[butyl[2-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-42-5 HCAPLUS
CN Acetic acid, [4-[[(2-methoxyethyl)[2-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-43-6 HCAPLUS
CN Acetic acid, [2-methyl-4-[[(1-oxobutyl)[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 637353-44-7 HCAPLUS
CN Acetic acid, [2-methyl-4-[[(propylsulfonyl)[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 637353-45-8 HCAPLUS
CN Acetic acid, [4-[[butyl[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]amino]sulfonyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-46-9 HCAPLUS
CN Acetic acid, [2-methyl-4-[[pentyl[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]amino]sulfonyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 637353-47-0 HCAPLUS
CN Acetic acid, [4-[[(2-cyclopropylethyl)[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]amino]sulfonyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-48-1 HCAPLUS
CN Acetic acid, [4-[[butyl[4-[4-(trifluoromethyl)phenyl]-2-pyrimidinyl]amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-49-2 HCAPLUS
CN Acetic acid, [4-[[butyl[4-(4-chlorophenyl)-2-pyrimidinyl]amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-50-5 HCAPLUS
CN Acetic acid, [4-[[(2-methoxyethyl)[4-[4-(trifluoromethyl)phenyl]-2-pyrimidinyl]amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-51-6 HCAPLUS
CN Acetic acid, [4-[[[4-(4-chlorophenyl)-2-pyrimidinyl](2-methoxyethyl)amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-52-7 HCAPLUS
CN Acetic acid, [2-methyl-4-[[propyl[4-[4-(trifluoromethyl)phenyl]-2-pyrimidinyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 637353-53-8 HCAPLUS
CN Acetic acid, [4-[[butyl[6-[4-(trifluoromethyl)phenyl]pyrazinyl]amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-54-9 HCAPLUS
CN Acetic acid, [4-[[butyl[6-(4-methylphenyl)pyrazinyl]amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-55-0 HCAPLUS
CN Acetic acid, [4-[[(2-methoxyethyl)[6-[4-(trifluoromethyl)phenyl]pyrazinyl]amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-56-1 HCAPLUS
CN Acetic acid, [4-[[butyl(2,4'-dimethyl[1,1'-biphenyl]-3-yl)amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-57-2 HCAPLUS
CN Acetic acid, [4-[[butyl(4'-fluoro-2-methyl[1,1'-biphenyl]-3-yl)amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-58-3 HCAPLUS
CN Acetic acid, [4-[[butyl(4'-cyano-2-methyl[1,1'-biphenyl]-3-yl)amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-59-4 HCAPLUS
CN Acetic acid, [4-[[butyl(4'-methoxy-2-methyl[1,1'-biphenyl]-3-yl)amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-60-7 HCAPLUS
CN Acetic acid, [4-[[butyl(4'-chloro-2-methyl[1,1'-biphenyl]-3-yl)amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-61-8 HCAPLUS
CN Acetic acid, [4-[[(4'-chloro-2-methyl[1,1'-biphenyl]-3-yl)(2-methoxyethyl)amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-62-9 HCAPLUS
CN Acetic acid, [4-[[(2,4'-dimethyl[1,1'-biphenyl]-3-yl)(2-methoxyethyl)amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-63-0 HCAPLUS
CN Acetic acid, [4-[[(2-methoxyethyl)(4'-methoxy-2-methyl[1,1'-biphenyl]-3-yl)amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-64-1 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[2-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]propylamino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 637353-65-2 HCAPLUS
CN Acetic acid, [4-[[(4'-chloro-2-methyl[1,1'-biphenyl]-3-yl)propylamino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-66-3 HCAPLUS
CN Acetic acid, [4-[[(2,4'-dimethyl[1,1'-biphenyl]-3-yl)propylamino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-67-4 HCAPLUS
CN Acetic acid, [4-[[(4'-fluoro-2-methyl[1,1'-biphenyl]-3-yl)propylamino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-68-5 HCAPLUS
CN Acetic acid, [4-[[(4'-cyano-2-methyl[1,1'-biphenyl]-3-yl)propylamino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-69-6 HCAPLUS
CN Acetic acid, [4-[[(4'-methoxy-2-methyl[1,1'-biphenyl]-3-yl)propylamino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-70-9 HCAPLUS
CN Acetic acid, [4-[[butyl[5-methyl-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-71-0 HCAPLUS
CN Acetic acid, [4-[[butyl[6-(4-methoxyphenyl)-5-methyl-4-pyrimidinyl]amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-72-1 HCAPLUS
CN Acetic acid, [4-[[butyl[5-methyl-6-(4-methylphenyl)-4-pyrimidinyl]amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-73-2 HCAPLUS
CN Acetic acid, [4-[[butyl[6-(4-chlorophenyl)-5-methyl-4-pyrimidinyl]amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-74-3 HCAPLUS
CN Acetic acid, [4-[[butyl[6-(4-chlorophenyl)pyrazinyl]amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-75-4 HCAPLUS
CN Acetic acid, [4-[[[6-(4-chlorophenyl)pyrazinyl](2-methoxyethyl)amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-76-5 HCAPLUS
CN Acetic acid, [2-methyl-4-[[propyl[6-[4-(trifluoromethyl)phenyl]pyrazinyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 637353-77-6 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[5-methyl-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]propylamino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 637353-78-7 HCAPLUS
CN Acetic acid, [4-[[[6-(4-chlorophenyl)-5-methyl-4-pyrimidinyl]propylamino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-79-8 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[5-methyl-6-(4-methylphenyl)-4-pyrimidinyl]propylamino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 637353-80-1 HCAPLUS
CN Acetic acid, [4-[[[6-(4-methoxyphenyl)-5-methyl-4-pyrimidinyl]propylamino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-81-2 HCAPLUS
CN Acetic acid, [4-[[butyl[6-[4-(trifluoromethyl)phenyl]pyrazinyl]amino]methyl]-2-ethylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-82-3 HCAPLUS
CN Acetic acid, [2-ethyl-4-[[(2-methoxyethyl)[6-[4-(trifluoromethyl)phenyl]pyrazinyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 637353-83-4 HCAPLUS
CN Acetic acid, [4-[[butyl[5-methyl-6-(4-methylphenyl)-4-pyrimidinyl]amino]methyl]-2-ethylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-84-5 HCAPLUS
CN Acetic acid, [4-[[butyl[2-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]amino]sulfonyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-85-6 HCAPLUS
CN Acetic acid, [4-[[butyl[6-(4-chlorophenyl)-5-methyl-4-pyrimidinyl]amino]methyl]-2-ethylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-86-7 HCAPLUS
CN Acetic acid, [4-[[butyl[5-methyl-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]-2-ethylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-87-8 HCAPLUS
CN Acetic acid, [2-ethyl-4-[[(2-methoxyethyl)[4-[4-(trifluoromethyl)phenyl]-2-pyrimidinyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 637353-88-9 HCAPLUS
CN Acetic acid, [2-methyl-4-[[2-propenyl[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)




```
=> d his

     (FILE 'HOME' ENTERED AT 01:40:31 ON 06 FEB 2006)

     FILE 'REGISTRY' ENTERED AT 01:40:40 ON 06 FEB 2006
L1              STRUCTURE UPLOADED
L2            0 S L1
L3          186 S L1 FULL

     FILE 'HCAPLUS' ENTERED AT 01:47:01 ON 06 FEB 2006
L4           30 S L3
L5            1 S L4 AND BESWICK, P?/AU

=> s l4 not l5
L6           29 L4 NOT L5

=> s l6 and harling, j?/au
             65 HARLING, J?/AU
L7            0 L6 AND HARLING, J?/AU

=> s l6 and kleanthous, s?/au
              9 KLEANTHOUS, S?/AU
L8            0 L6 AND KLEANTHOUS, S?/AU

=> s l6 and lambert, m?/au
            937 LAMBERT, M?/AU
L9            0 L6 AND LAMBERT, M?/AU

=> s l6 and patel, v?/au
           1064 PATEL, V?/AU
L10           0 L6 AND PATEL, V?/AU

=> s l6 and simpson, j?/au
           2313 SIMPSON, J?/AU
L11           0 L6 AND SIMPSON, J?/AU

=> d l6, ibib abs hitstr, 1-29

L6   ANSWER 1 OF 29  HCAPLUS  COPYRIGHT 2006 ACS on STN
```

Full Text | Citing References

```
ACCESSION NUMBER:        2006:53048  HCAPLUS
TITLE:                   Preparation of N-(2-oxoazepan-3-yl)sulfonamides as
                         γ-secretase inhibitors for treating Alzheimer's
                         disease and cancers
INVENTOR(S):             Galley, Guido; Kitas, Eric, Argirios; Jakob-Roetne,
                         Roland
```

PATENT ASSIGNEE(S): F. Hoffmann-La Roche AG, Switz.
SOURCE: PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006005486	A1	20060119	WO 2005-EP7268	20050706
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2006014945	A1	20060119	US 2005-179703	20050712
PRIORITY APPLN. INFO.:			EP 2004-103339 A	20040713

GI



AB Title compds. I [R1 = (un)substituted hetero/aryl; R2-R4, R2'-R4' = H, lower alkyl, Ph or lower alkyl substituted by halogen; R5 = cycloalkyl, (un)substituted hetero/aryl; X = CHR; R = H, lower alkyl; and their pharmaceutically suitable acid addn. salts, optical pure enantiomers, racemates or diastereomeric] were prepd. as γ-secretase inhibitors. Thus, reductive amination of 3-fluoro-p-anisaldehyde with 3-aminoazepan-2-one and reaction with 5-chlorothiophene-2-sulfonyl chloride gave sulfonamide II. Preferred I inhibited γ-secretase with IC50 < 0.3 μM. I are useful in the treatment of Alzheimer's disease or common cancers.

IT 873373-47-8P 873373-55-8P 873373-64-9P
873373-71-8P 873373-74-1P 873373-90-1P
873373-91-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of N-(2-oxoazepan-3-yl)sulfonamides as γ-secretase inhibitors for treating Alzheimer's disease and cancers)

RN 873373-47-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 873373-55-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 873373-64-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 873373-71-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 873373-74-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 873373-90-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 873373-91-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2005:980891 HCAPLUS
DOCUMENT NUMBER: 143:379070
TITLE: Minor structural modifications convert a selective PPARα agonist into a potent, highly selective PPARδ agonist
AUTHOR(S): Weigand, Stefan; Bischoff, Hilmar; Dittrich-Wengenroth, Elke; Heckroth, Heike; Lang, Dieter; Vaupel, Andrea; Woltering, Michael
CORPORATE SOURCE: Pharma Research, BAYER Health Care AG, Wuppertal, D-42096, Germany
SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(20), 4619-4623
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB We report the solid-phase synthesis and pharmacol. evaluation of a new series of small-mol. agonists of the human peroxisome proliferator-activated receptor δ (PPARδ) based on a lead structure from our PPARα program. Compd. I showed good pharmacokinetics.

IT **866820-82-8P**
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(solid-phase prepn. of small-mol. PPARδ agonists and evaluation for possible use for metabolic disorder treatment)

RN 866820-82-8 HCAPLUS

CN Propanoic acid, 2-[4-[[[2-[(2,4-dichlorophenyl)amino]-2-oxoethyl]phenylamino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2005:921438 HCAPLUS
DOCUMENT NUMBER: 143:259498
TITLE: Discovery and structure-activity relationships of novel sulfonamides as potent PTP1B inhibitors
AUTHOR(S): Holmes, Christopher P.; Li, Xianfeng; Pan, Yijun; Xu, Caiding; Bhandari, Ashok; Moody, Claire M.; Miguel, Joy A.; Ferla, Steven W.; De Francisco, M. Nuria; Frederick, Brian T.; Zhou, Siqun; Macher, Natalie; Jang, Larry; Irvine, Jennifer D.; Grove, J. Russell
CORPORATE SOURCE: Affymax, Inc., Palo Alto, CA, 94304, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(19), 4336-4341
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A series of novel sulfonamides contg. a single difluoromethylene-phosphonate group were discovered to be potent inhibitors of protein

tyrosine phosphatase 1B. Structure-activity relationships around the scaffold were investigated, leading to the identification of compds. with IC50 or Ki values in the low nanomolar range. These sulfonamide-based inhibitors exhibit 100 and 30 times higher inhibitory activity than the corresponding tertiary amines and carboxamides, resp.

IT **863977-05-3P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(discovery and structure-activity relationships of novel sulfonamides as potent PTP1B inhibitors)

RN 863977-05-3 HCAPLUS

CN Acetic acid, [4-[[[[4-(difluorophosphonomethyl)phenyl]methyl][4-(1,2,3-thiadiazol-4-yl)phenyl]amino]sulfonyl]phenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2005:238962 HCAPLUS
DOCUMENT NUMBER: 142:316838
TITLE: Preparation of azole compounds as PPARα agonists
INVENTOR(S): Yamazaki, Yukiyoshi; Toma, Tsutomu; Nishikawa, Masahiro; Ozawa, Hidefumi; Okuda, Ayumu; Araki, Takaaki; Abe, Kazutoyo; Oda, Soichi
PATENT ASSIGNEE(S): Kowa Co., Ltd., Japan
SOURCE: PCT Int. Appl., 184 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005023777	A1	20050317	WO 2004-JP12750	20040902

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,

SN, TD, TG

US 2005101636	A1	20050512	US 2004-933467		20040903
PRIORITY APPLN. INFO.:			US 2003-499357P	P	20030903
			JP 2003-317353	A	20030909
			JP 2003-364817	A	20031024

OTHER SOURCE(S): MARPAT 142:316838
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1, R2 = H, Me, ethyl; R3a, R3b, R4a, R4b = H, halo, nitro, etc.; Y = carbonyl, carbonylamino, aminocarbonyl, etc.; X = O, S, NR5; R5 = H, alkyl, alkylsulfonyl, etc.; Z = CH, N; n = 1-6; m = 2-6] were prepd. Thus, compd. II was prepd. from 2-iodophenylisothiocyanate in a multistep process. In PPARα (peroxisome proliferator-activated receptor α) activation assays, the EC50 value of compd. II was 0.001 μM. Compds. I are claimed useful for the treatment of hyperlipidemia, arteriosclerosis, etc.

IT **848258-23-1P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of azole compds. as PPARα agonists for treatment of hyperlipidemia, arteriosclerosis, etc.)

RN 848258-23-1 HCAPLUS
CN Benzenepropanoic acid, 4-[[2-benzoxazolyl[3-[4-[(methylsulfonyl)oxy]phenoxy]propyl]amino]methyl]-α,α-dimethyl- (9CI) (CA INDEX NAME)



IT **848258-20-8P** **848258-24-2P** **848258-37-7P**
848258-38-8P **848258-46-8P** **848258-51-5P**
848258-52-6P **848258-53-7P** **848258-54-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of azole compds. as PPARα agonists for treatment of hyperlipidemia, arteriosclerosis, etc.)

RN 848258-20-8 HCAPLUS
CN Propanoic acid, 2-[4-[[2-benzoxazolyl[2-[3-(dimethylamino)phenoxy]ethyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 848258-24-2 HCAPLUS
CN Benzenepropanoic acid, 4-[[2-benzoxazolyl[3-[4-[(methylsulfonyl)oxy]phenoxy]propyl]amino]methyl]-α,α-dimethyl-, sodium salt (9CI) (CA INDEX NAME)



RN 848258-37-7 HCAPLUS
CN Propanoic acid, 2-[4-[[2-benzoxazolyl[3-[3-(dimethylamino)phenoxy]propyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 848258-38-8 HCAPLUS
CN Propanoic acid, 2-[4-[[2-benzoxazolyl[3-[3-(dimethylamino)phenoxy]propyl]amino]methyl]phenoxy]-2-methyl-, sodium salt (9CI) (CA INDEX NAME)



RN 848258-46-8 HCAPLUS
CN Propanoic acid, 2-[4-[[2-benzoxazolyl(2-phenoxyethyl)amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 848258-51-5 HCAPLUS
CN Propanoic acid, 2-[4-[[2-benzoxazolyl[2-(4-methoxyphenoxy)ethyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 848258-52-6 HCAPLUS
CN Propanoic acid, 2-[4-[[2-benzoxazolyl[3-(4-methoxyphenoxy)propyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 848258-53-7 HCAPLUS
CN Propanoic acid, 2-[4-[[2-benzoxazolyl[2-(4-chlorophenoxy)ethyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 848258-54-8 HCAPLUS
CN Propanoic acid, 2-[4-[[2-benzoxazolyl[3-(4-chlorophenoxy)propyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN

Full Text | More References

ACCESSION NUMBER: 2005:141355 HCAPLUS

DOCUMENT NUMBER: 142:214871
TITLE: Novel chemiluminescent compounds and their use in immunoassays
INVENTOR(S): Heindl, Dieter; Herrmann, Rupert; Jenni, Wolfgang; Maerz, Heribert
PATENT ASSIGNEE(S): Roche Diagnostics G.m.b.H., Germany; F.Hoffmann-La Roche A.-G.
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005015214	A1	20050217	WO 2004-EP8413	20040728

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: EP 2003-16621 A 20030730
OTHER SOURCE(S): MARPAT 142:214871
GI



I

AB The present invention relates to novel chemiluminescent compds. (I), to a method for synthesizing these compds., to derivs. and conjugates comprising these compds., to the use of these compds. or conjugates thereof in chemiluminescence based assays, esp. in immunoassays; wherein the fused rings I or II represent an arom. five ring heterocycle or an aryl ring, resp., with the proviso that at least one of I or II is an arom. five ring heterocycle, R1 and R2 independently represent hydrogen, R, halogen, -NR2, -OR, -OH, -S(O)2OH, -CN, -SCN, -SSR, -SR, -C(O)R, -C(O)H, -C(O)OR, -C(O)OH, -NHC(O)R, -C(O)NHR, -C(O)NH2, -S(O)2NHR or -S(O)2NH2; and R represents alkyl, alkenyl, alkynyl or aralkyl, wherein the alkyl, alkenyl or alkynyl can contain up to 20 hetero atoms, R3 represents alkyl, alkenyl, alkynyl or aralkyl, wherein the alkyl, alkenyl or alkynyl can contain up to 20 hetero atoms, and may also contain a coupling moiety, Z represents a leaving group, and A, if required, represents a counter-ion to balance a net charge of the compd. Thus, N1-methyl-N-(4-methoxphenyl)-N-(succinimidyloxycarbonylpropylsulfonyl)thieno[2,3-b]quinolinium-4-

carboxamide trifluoromethylsulfonate was prepd. and used for prepn. of an anti-TSH conjugate and monoclonal antibody against TSH.

IT **842129-95-7P**, N-(4-Methoxyphenyl)-N-(carboxypropylsulfonyl)furo[2,3-b] quinoline-4-carboxamide **842130-00-1P**, N-(4-Methoxyphenyl)-N-(carboxypropylsulfonyl)thieno[2,3-b]quinoline-4-carboxamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of novel chemiluminescent compds. for immunoassays)

RN 842129-95-7 HCAPLUS

CN Benzenepropanoic acid, 4-[[(furo[2,3-b]quinolin-4-ylcarbonyl)(4-methoxyphenyl)amino]sulfonyl]- (9CI) (CA INDEX NAME)



RN 842130-00-1 HCAPLUS

CN Benzenepropanoic acid, 4-[[(4-methoxyphenyl)(thieno[2,3-b]quinolin-4-ylcarbonyl)amino]sulfonyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2004:1059311 HCAPLUS

DOCUMENT NUMBER: 142:38016

TITLE: Preparation of 2-amino-1-(4-hydroxyphenyl)propanol derivatives as highly selective agonists of β3 adrenergic receptor

INVENTOR(S): Ishikawa, Takehiro; Muranaka, Hideyuki; Nakamura,

Tetsuya; Kobayashi, Junichi; Suzuki, Ritsu; Ozawa, Tomonaga; Tamai, Tetsuro; Akahane, Satoshi
PATENT ASSIGNEE(S): Kissei Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004106290	A1	20041209	WO 2004-JP6757	20040513

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: JP 2003-135523 A 20030514
OTHER SOURCE(S): MARPAT 142:38016
GI



AB Amino alcs. represented by the general formula (I) [wherein R1, R2 = H, halo, lower alkyl, halo-lower alkyl,lower alkoxy, HO, cyano, NO2, NH2, CONH2, mono- or dialkylamino or -carbamoyl, lower acylamino; R3 = H, (un)substituted lower alkyl; R4, R5, R6 = H, halo, halo, lower alkyl, halo-lower alkyl, hydroxy-lower alkyl, cycloalkyl, heterocycloalkyl, lower alkoxy, HO, di(lower alkyl)amino, cyclic amino, di(lower alkyl)amino-lower alkyl, aryl, aryloxy, aralkyloxy, heteroaryl, cyano, lower acyl lower alkylsulfanyl, lower alkylsufonyl, COR7, -A1-COR7, -O-A2-COR7, -NHCOR8, NHCONHR9; R7 = HO, lower alkoxy, aralkyloxy, NH2, mono- or di(lower alkyl)amino, cyclic amino; A1 = lower alkylene or alkenylene; A2 = lower alkylene; R8 = H, lower alkyl, lower alkoxy; R9 = lower alkyl, cycloalkyl, cycloalkyl-lower alkyl, X = a bond, O; n = 2-5] or pharmacol. acceptable salts thereof. These compds. have potent β3-adrenergic receptor stimulating activity and high selectivity for the receptor and are useful for treating or preventing obesity, diabetes, hyperlipidemia, depression, urinary disorders, diseases caused by gallstone or biliary tract

hyperactivity, or diseases caused by increased function of digestive tract. Thus, N-tosylation of 4-[(1R,2S)-2-[[2-(4-aminophenyl)ethyl]-tert-butoxycarbonylamino]-1-hydroxypropyl]phenyl acetate (prepn. given) by p-toluenesulfonyl chloride in the presence of pyridine in CH2Cl2 followed by treatment with CF3CO2H/CH2Cl2 and then NH3/MeOH and chromatog. purifn. using a reversed phase column (CAPCELL PAK C18) gave N-[4-[2-[2-[(1S,2R)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-4-methylbenzenesulfonamide (II) (wherein R10 = Me, R11 = H). II (wherein R10 = CO2H, R11 = Cl) showed agonist activity with ED50 of 0.94, 7.45, and 10-10 to 2 X 10 -4 M for human β3, β2, and β1 adrenergic receptor, resp.

IT **805235-21-6P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of amino(hydroxyphenyl)propanol derivs. as highly selective β3 adrenergic receptor agonists)

RN 805235-21-6 HCAPLUS

CN Acetic acid, [4-[[butyl[4-[2-[[(1S,2R)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl]phenyl]amino]sulfonyl]phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2004:581027 HCAPLUS
DOCUMENT NUMBER: 141:253650
TITLE: Bile acid conjugates of a nonsteroidal glucocorticoid receptor modulator
AUTHOR(S): Tu, Noah; Link, J. T.; Sorensen, Bryan K.; Emery, Maurice; Grynfarb, Marlena; Goos-Nilsson, Annika; Nguyen, Bach
CORPORATE SOURCE: Metabolic Disease Research, Abbott Laboratories, Abbott Park, IL, 60064-6098, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(16), 4179-4183
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Bile acid conjugates of a selective nonsteroidal glucocorticoid receptor modulator were prepd. and evaluated. Potent GR binding conjugates that showed improved metabolic stability were discovered. However, cellular potency and pharmacokinetics were not substantially improved.

IT **756843-49-9P** **756843-52-4P**

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic

preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(bile acid conjugates of nonsteroidal glucocorticoid receptor modulator)

RN 756843-49-9 HCAPLUS
CN Benzenepropanoic acid, 4-[[[2-methyl-3-[(methylsulfonyl)amino]phenyl](phenylmethyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 756843-52-4 HCAPLUS
CN Benzenepropanoic acid, 4-[[[2-methyl-3-[(methylsulfonyl)amino]phenyl][(4-phenoxyphenyl)methyl]amino]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2004:565187 HCAPLUS
DOCUMENT NUMBER: 141:123486
TITLE: Preparation of naphthalene derivatives as selective estrogen receptor modulators
INVENTOR(S): Hamaoka, Shinichi; Kitazawa, Noritaka; Nara, Kazumasa; Sasaki, Atsushi; Kamada, Atsushi; Okabe, Tadashi
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
SOURCE: PCT Int. Appl., 982 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058682	A1	20040715	WO 2003-JP16808	20031225

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,

TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2512000	AA	20040715	CA 2003-2512000	20031225
EP 1577288	A1	20050921	EP 2003-782904	20031225

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRIORITY APPLN. INFO.:	JP 2002-378729	A	20021226
	WO 2003-JP16808	W	20031225

OTHER SOURCE(S): MARPAT 141:123486

GI



AB The title compds. I [wherein T = a single bond, (un)substituted alkylene, alkenylene, or alkynylene; A = a single bond, (un)substituted heterocycle, (hetero)arylene, or cyclohydrocarbyl; Y = a single bond, O, S, etc.; Z = CH2O, O, S, etc.; ring G = (hetero)arylene, heterocycle, etc.; Q1 and Q2 = independently N or C; Ra and Rb = independently H, (un)substituted alkyl, alkenyl, alkynyl, etc.; W = a single bond, CO, (un)substituted alkylene, NH, etc.; R' = H, O, S, etc.; R'' = H, OH, halo, etc.; R = H, OH, halo, etc.; L = a single bond, (un)substituted alkylene, alkenylene, or alkynylene] or salts, or hydrates thereof are prepd. as selective estrogen receptor modulators. For example, the compd. II was prepd. in a multi-step synthesis. I showed affinity towards estrogen receptor with Ki of 0.2 to 94 nM in cow.

IT **722537-68-0P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of naphthalene derivs. as selective estrogen receptor modulators)

RN 722537-68-0 HCAPLUS

CN Acetic acid, [4-[[ethyl[5-methoxy-2-(1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl)phenyl]amino]carbonyl]phenoxy]- (9CI) (CA INDEX NAME)



L6 ANSWER 9 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2004:412803 HCAPLUS
DOCUMENT NUMBER: 141:1264
TITLE: Receptor function controlling agent
INVENTOR(S): Fukatsu, Kohji; Sasaki, Shinobu; Hinuma, Shuji; Ito, Yasuaki; Suzuki, Nobuhiro; Harada, Masataka; Yasuma, Tsuneo
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 442 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004041266	A1	20040521	WO 2003-JP14139	20031106
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2505322	AA	20040521	CA 2003-2505322	20031106
JP 2005015461	A2	20050120	JP 2003-376833	20031106
EP 1559422	A1	20050803	EP 2003-810621	20031106
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.:

JP 2002-324632	A	20021108
JP 2003-16889	A	20030127
JP 2003-153986	A	20030530
WO 2003-JP14139	W	20031106

OTHER SOURCE(S): MARPAT 141:1264

AB A GPR40 receptor function controlling agent which contains a compd. having an arom. ring and a group capable of releasing a cation and is useful as a insulin secretion promoting agent or a preventive/remedy for diabetes, etc.

IT **691903-92-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(GPR40 receptor function controlling agents as antidiabetics)

RN 691903-92-1 HCAPLUS

CN Benzenepropanoic acid, 4-[[methyl(4-phenyl-2-thiazolyl)amino]methyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 10 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2004:2833 HCAPLUS
DOCUMENT NUMBER: 140:77141
TITLE: Preparation of 2-[4-(heteroarylaminomethyl)phenoxy]-2-methylpropanoates for treating a hPPAR mediated diseases
INVENTOR(S): Dodic, Nerina; Dumaitre, Bernard Andre; Gellibert, Francoise Jeanne; Sierra, Michael Lawrence
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000785	A2	20031231	WO 2003-EP6417	20030618
WO 2004000785	A3	20041014		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1513796	A2	20050316	EP 2003-735642	20030618
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005529965	T2	20051006	JP 2004-514763	20030618
US 2005222424	A1	20051006	US 2004-518347	20041217
PRIORITY APPLN. INFO.:			GB 2002-14139 A	20020619
			WO 2003-EP6417 W	20030618

OTHER SOURCE(S): MARPAT 140:77141
GI



AB The title compds. [I; R1, R2 = H, alkyl; R3, R4 = H, alkyl, OMe, CF, allyl, halo; n = 0-1; at least of X, Z and Y = O, S, N; R6 = alkyl, CF3, OMe, OCF3, halo; y = 0-5; R7 = H, CF3, alkyl (optionally substituted by phenyl), alkenyl with the proviso that when Z = S, O, R7 = H; R10 = H, alkyl; R5 = H, alkyl, alkoxyalkyl, alkenyl, alkoxy, etc.], useful for treatment of a hPPAR disease or condition such as dyslipidemia, syndrome X, heart failure, hypercholesterolemia, cardiovascular disease, diabetes, insulin resistance, hyperlipidemia, obesity, anorexia bulimia and anorexia nervosa (no biol. data given), were prepd. Thus, reacting Et 2-(4-bromomethyl-2,6-dimethylphenoxy)-2-methylpropionate with [4-methyl-2-(4-trifluoromethylphenyl)thiazol-5-yl]thiophen-3-ylmethylamine (prepns. given) in the presence of cesium carbonate in 3-methyl-2-butanone followed by hydrolysis afforded II. Pharmaceutical compn. comprising the compd. I.

IT **639783-41-8P** **639783-43-0P** **639783-45-2P**
639783-47-4P **639783-49-6P** **639783-51-0P**
639783-53-2P **639783-56-5P** **639783-58-7P**
639783-60-1P **639783-62-3P** **639783-98-5P**
639784-00-2P **639784-02-4P** **639784-04-6P**
639784-06-8P **639784-08-0P** **639784-10-4P**
639784-12-6P **639784-14-8P** **639784-16-0P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 2-[4-(heteroarylaminomethylphenoxy])-2-methylpropanoates for treating a hPPAR mediated diseases)

RN 639783-41-8 HCAPLUS

CN Propanoic acid, 2-[2,6-dimethyl-4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl](3-thienylmethyl)amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 639783-43-0 HCAPLUS
CN Propanoic acid, 2-[4-[[[3-(4-chlorophenyl)-1-methyl-1H-pyrazol-5-yl](3-thienylmethyl)amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 639783-45-2 HCAPLUS
CN Propanoic acid, 2-[4-[[[3-(4-chlorophenyl)-1-methyl-1H-pyrazol-5-yl]methylamino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 639783-47-4 HCAPLUS
CN Propanoic acid, 2-[4-[[[(2-chlorophenyl)methyl][3-(4-chlorophenyl)-1-methyl-1H-pyrazol-5-yl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 639783-49-6 HCAPLUS
CN Propanoic acid, 2-[4-[[[(4-methoxyphenyl)methyl][1-methyl-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 639783-51-0 HCAPLUS
CN Propanoic acid, 2-[2,6-dimethyl-4-[[[1-methyl-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl](3-thienylmethyl)amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 639783-53-2 HCAPLUS
CN Propanoic acid, 2-[4-[[[(4-fluorophenyl)methyl][1-methyl-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 639783-56-5 HCAPLUS
CN Propanoic acid, 2-[4-[[[3-(4-chlorophenyl)-1-methyl-1H-pyrazol-5-yl]ethylamino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 639783-58-7 HCAPLUS
CN Propanoic acid, 2-[4-[[[(4-methoxyphenyl)methyl][4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 639783-60-1 HCAPLUS
CN Propanoic acid, 2-[4-[[[(2-chlorophenyl)methyl][4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 639783-62-3 HCAPLUS
CN Propanoic acid, 2-[4-[[[(4-fluorophenyl)methyl][4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 639783-98-5 HCAPLUS
CN Propanoic acid, 2-[4-[[[(4-methoxyphenyl)methyl][4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]amino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 639784-00-2 HCAPLUS
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl](2-thienylmethyl)amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 639784-02-4 HCAPLUS
CN Propanoic acid, 2-[4-[[(2-furanylmethyl)[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]amino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 639784-04-6 HCAPLUS
CN Propanoic acid, 2-[4-[[[(2-methoxyphenyl)methyl][4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]amino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 639784-06-8 HCAPLUS
CN Propanoic acid, 2-[4-[[[(3-methoxyphenyl)methyl][4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]amino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 639784-08-0 HCAPLUS
CN Propanoic acid, 2-[4-[[[(2-fluorophenyl)methyl][4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]amino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 639784-10-4 HCAPLUS
CN Propanoic acid, 2-[4-[[[(2-chlorophenyl)methyl][4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]amino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 639784-12-6 HCAPLUS
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[methyl[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 639784-14-8 HCAPLUS
CN Propanoic acid, 2-[4-[[[(2-fluorophenyl)methyl][1-methyl-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]amino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 639784-16-0 HCAPLUS
CN Propanoic acid, 2-[4-[[[(2-methoxyphenyl)methyl][1-methyl-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]amino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



L6 ANSWER 11 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN

Full Text | Other References

ACCESSION NUMBER: 2003:922669 HCAPLUS
DOCUMENT NUMBER: 139:395923
TITLE: Preparation of benzoxazoles as PPARα agonists
INVENTOR(S): Yamazaki, Yukiyoshi; Toma, Tsutomu; Nishikawa, Masahiro; Ozawa, Hidefumi; Okuda, Ayumu; Abe, Kazutoyo; Oda, Soichi
PATENT ASSIGNEE(S): Kowa Co., Ltd., Japan
SOURCE: U.S., 63 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6653334	B1	20031125	US 2002-329547	20021227
JP 2004210776	A2	20040729	JP 2003-428197	20031224
EP 1433786	A1	20040630	EP 2003-29917	20031229
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.: US 2002-329547 A 20021227
OTHER SOURCE(S): MARPAT 139:395923
GI



I

II

AB The title compds. [I; R1 = H, alkyl, arylalkyl, etc.; R2, R3 = H, Me, Et; n = 1-3] and their salts, which selectively activate PPARα, and are useful in preventing and/or treating hyperlipidemia, arteriosclerosis, diabetes, inflammation and heart diseases, were prepd. E.g., a 4-step synthesis of II (starting from 3-hydroxybenzaldehyde and Et 2-bromoisobutyrate) which showed EC50 of 0.001 μM, 0.2 μM and >10 μM with respect to hPPARα, hPPARγ and hPPARδ, resp., was given. Pharmaceutical compn. comprising the compd. I is claimed.

IT 627095-17-4P 627095-18-5P 627095-19-6P
627095-20-9P 627095-21-0P 627095-22-1P
627095-23-2P 627095-27-6P 627095-28-7P
627095-37-8P 627095-38-9P 627096-48-4P
627096-49-5P 627096-50-8P 627096-51-9P
627096-52-0P 627096-53-1P 627096-54-2P
627096-55-3P 627096-56-4P 627096-57-5P
627096-58-6P 627096-59-7P 627096-60-0P
627096-61-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of benzoxazoles as PPARα agonists)

RN 627095-17-4 HCAPLUS
CN Propanoic acid, 2-[4-[[2-benzoxazolyl[[4-(phenylmethoxy)phenyl]methyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 627095-18-5 HCAPLUS
CN Propanoic acid, 2-[4-[[2-benzoxazolyl[(4-methoxyphenyl)methyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 627095-19-6 HCAPLUS
CN Propanoic acid, 2-[4-[[2-benzoxazolyl[(4-nitrophenyl)methyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 627095-20-9 HCAPLUS
CN Propanoic acid, 2-[4-[[2-benzoxazolyl(1-naphthalenylmethyl)amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 627095-21-0 HCAPLUS
CN Propanoic acid, 2-[4-[[2-benzoxazolyl(2-ethoxy-2-oxoethyl)amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 627095-22-1 HCAPLUS
CN Propanoic acid, 2-[4-[(2-benzoxazolyl-2-butynylamino)methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 627095-23-2 HCAPLUS
CN Propanoic acid, 2-[4-[(2-benzoxazolyl-5-hexenylamino)methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 627095-27-6 HCAPLUS
CN Propanoic acid, 2-[4-[[2-benzoxazolyl[[2-[(phenylsulfonyl)methyl]phenyl]methyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 627095-28-7 HCAPLUS
CN Propanoic acid, 2-[4-[[2-benzoxazolyl(cyclohexylmethyl)amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 627095-37-8 HCAPLUS
CN Propanoic acid, 2-[4-[[2-benzoxazolyl[(2-nitrophenyl)methyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 627095-38-9 HCAPLUS
CN Propanoic acid, 2-[4-[[2-benzoxazolyl[(2-methyl-3-nitrophenyl)methyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 627096-48-4 HCAPLUS
CN Propanoic acid, 2-[4-[(2-benzoxazolylmethylamino)methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 627096-49-5 HCAPLUS
CN Propanoic acid, 2-[4-[(2-benzoxazolylethylamino)methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 627096-50-8 HCAPLUS
CN Propanoic acid, 2-[4-[(2-benzoxazolylpropylamino)methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 627096-51-9 HCAPLUS
CN Propanoic acid, 2-[4-[(2-benzoxazolylbutylamino)methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 627096-52-0 HCAPLUS
CN Propanoic acid, 2-[4-[(2-benzoxazolylpentylamino)methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 627096-53-1 HCAPLUS
CN Propanoic acid, 2-[4-[[2-benzoxazolyl(3-methylbutyl)amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 627096-54-2 HCAPLUS
CN Propanoic acid, 2-[4-[(2-benzoxazolylhexylamino)methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 627096-55-3 HCAPLUS
CN Propanoic acid, 2-[4-[(2-benzoxazolylheptylamino)methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 627096-56-4 HCAPLUS
CN Propanoic acid, 2-[4-[(2-benzoxazolyloctylamino)methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 627096-57-5 HCAPLUS
CN Propanoic acid, 2-[4-[[2-benzoxazolyl(cyclopropylmethyl)amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 627096-58-6 HCAPLUS
CN Propanoic acid, 2-[4-[[2-benzoxazolyl(3-phenylpropyl)amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 627096-59-7 HCAPLUS
CN Propanoic acid, 2-[4-[[2-benzoxazolyl(3-cyclohexylpropyl)amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 627096-60-0 HCAPLUS
CN Propanoic acid, 2-[4-[[2-benzoxazolyl(4-methylpentyl)amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 627096-61-1 HCAPLUS
CN Propanoic acid, 2-[4-[[[(2-aminophenyl)methyl]-2-benzoxazolylamino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 12 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2003:154382 HCAPLUS
DOCUMENT NUMBER: 138:187795
TITLE: Preparation of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivatives as antagonists of prostaglandin E2 (PEG2) receptors
INVENTOR(S): Tani, Kousuke; Asada, Masaki; Kobayashi, Kaoru; Narita, Masami; Ogawa, Mikio
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 1009 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2003016254	A1	20030227	WO 2002-JP8120	20020808
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2457468	AA	20030227	CA 2002-2457468	20020808
EP 1431267	A1	20040623	EP 2002-755874	20020808
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002011810	A	20040824	BR 2002-11810	20020808
CN 1551866	A	20041201	CN 2002-817376	20020808
ZA 2004000973	A	20050104	ZA 2004-973	20040205
NO 2004000564	A	20040510	NO 2004-564	20040206
PRIORITY APPLN. INFO.:			JP 2001-241867	A 20010809
			WO 2002-JP8120	W 20020808

OTHER SOURCE(S): MARPAT 138:187795

GI



AB Carboxylic acid derivs. (I) and nontoxic salts thereof [wherein R1 = CO2H, CO2R4, CH2OH, COR5SO2R6, CONH2, CH2NR5SO2R6, CH2NR9COR10, CH2NR9CONR5SO2R6, CH2SO2NR9COR10, CH2O2CNR5SO2R6, tetrazole, 1,2,4-oxadiazol-5-one, 1,2,4-oxadiazol-5-thione, 1,2,4-thiadiazol-5-one, etc. (wherein R4 = C1-6 alkyl, hydroxy-C1-4 alkyl, C1-4 alkoxy-C1-4 alkyl, carboxy-C1-4 alkyl, etc.; R5, R9 = H, C1-6 alkyl; R6 = C1-6 alkyl, C3-15 mono-, di-, or tricarbocyclic, 3- to 13-membered mono-, di-, or tricyclic heterocyclyl, etc.; R10 = H, R6); A = a single bond, C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, etc.; the ring B = C3-12 mono- or dicyclic carbocyclic ring, 3- to 12-membered mono- or dicyclic heterocyclic ring; R2 = C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C2-6 alkenyl, C2-6 alkynyl, halo, CHF2, CF3, NO2, cyano, Ph, oxo; m, n = 0,1,2; Q = (C1-4 alkylene, C2-4 alkenylene, or C2-4 alkynylene)-Cyc2, -C1-4 alkylene-Z-Cyc3, amino-C1-4 alkyl, cyano-C1-4 alkyl, acylamino-C1-4 alkyl, 3- to 7-membered monocyclic carbocyclyl, 3- to 6-membered monocyclic heterocyclyl, etc. (wherein Cyc2, Cyc3 = C3-15 mono-, di-, or tricyclic carbocyclyl or heterocyclyl, etc.; Z = O, S, SO, SO2, NH, NHCO, etc.); D = an linking chain consisting of 1-2 or 3-6 of atoms selected from C, N, O, or S, etc.; R3 = C1-6 alkyl, C3-15 mono-, di-, or tricyclic carbocyclyl, 3- to 15-membered mono-, di-, or tricyclic heterocyclyl, etc.] are prepd. These carboxylic acid derivs. include phenylpropanoic acid, phenylpropenoic acid, phenylpropanamide, phenylpropenamide, 3-oxoisoindolin-1-ylacetic acid, benzylbenzoic acid, benzylaminoacetic acid, pyrazolylmethylbenzoic acid, benzoylaminoacetic acid, (pyrazolylmethylphenyl)propenoic acid, pyrazolylmethylpropanoic acid, (pyridinyloxyphenyl)propanoic acid, phenoxyacetic acid, phenylbutanoic acid, (pyrazolylmethyl)propanamide, (piperazinylmethylphenyl)propanamide, (morpholinylmethylphenyl)propanamide , (pyridinyloxyphenyl)propanamide, (pyrazolylmethyl)propenamide (oxoimidazolidinylmethylphenyl)propanamide, (oxopyrrolidinylmethylphenyl)p

ropenamide, (thiophenylmethylphenyl)propenamide, (pyrazolylmethylphenylamino)acetamide, (thiazolylaminomethylphenyl)propanamide, thiophenylpropenamide, (pyrazolylmethylphenoxy)acetamide, (phenoxymethyl)benzamide, (pyrazolylmethylphenylethyl)-1,2,4-oxadiazol-5-one, and (pyrazolylmethylphenylindolyl)acetic acid. Because of binding to PEG2 receptors, in particular, subtype EP3 and/or subtype EP4 and having antagonism, the compds. I are useful in preventing and/or treating diseases such as pain, allodynia, hyperalgesia, pruritus (itching), urticaria, atopic dermatitis, contact dermatitis, Urushi (Japanese lacquer tree) dermatitis, allergic conjunctivitis, symptoms during dialysis, asthma, rhinitis, allergic rhinitis, nasal congestion, sneeze, psoriasis, pollakiuria (increased urinary frequency), urination disorder, ejaculation (semination) disorder, fever (pyrexia), systemic inflammation reaction, learning disorder, Alzheimer's disease, neovascularization, cancer formation, cancer proliferation, cancer metastasis to organs, cancer metastasis to bone, hypercalcemia accompanied by cancer metastasis to bone, retinopathy, rubrum, erythema (rash), leucoma, skin moth-patch, heat burn, burn, steroid burn, kidney failure, nephropathy, acute or chronic nephritis, blood electrolyte disorder, imminent abortion, threatened abortion, excessive menstruation, dysmenorrhea, endometriosis, premenstrual syndrome, uterine gland myopathy, reprodn. disorder, and stress. They are also useful in preventing and/or treating anxiety, depression, psychophysiol. disorder, mental retardation, thrombus, embolism, transient ischemic attack, cerebral infarction, atheroma, organ transplant, heart failure, hypertension, myocardial infarction, arteriosclerosis, circulation disorders or ulcers assocd. therewith, nerve disorders, vascular dementia, edema, diarrhea, constipation, biliary excretion disorder, ulcerative colitis, Crohn's disease, irritable bowel syndrome, redn. of rebound after using steroid drugs, aids for decreasing or removing steroid drugs, bone diseases, systemic granuloma, immune diseases, pyorrhea alveolaris, gingivitis, periodontal disease, nerve cell death, lung disorder, liver disorder, acute hepatitis, myocardial ischemia, Kawasaki disease, multiple organ failure, chronic headache, angiitis, venous failure, varicose vein (varicosis), anal fistula, diabetes insipidus, neonatal patent ductus arteriosus, and cholelithiasis. Thus, 4-hydroxymethyl-2-[2-(naphthalen-2-yl)ethoxy]cinnamic acid Et ester was mesylated by methanesulfonyl chloride in the presence of Et3N in THF at 0? for 15 min and condensed with pyrazole in the presence of NaH in DMF at 0? to give 2-[2-(naphthalen-2-yl)ethoxy]-4-(1-pyrazolylmethyl)cinnamic acid Et ester. 4-[2-[[2-(Naphthalen-1-yl)propanoyl]amino]-4-methylthiomethylphenyl]butanoic acid inhibited the binding of [3H]PGE2 to prostaglandin E2 (PEG2) receptor subtype EP1, Ep2, EP3, and EP4 expressed in CHO cells with Ki of >10, >10, 0.27, and 0.038 μM, resp. A tablet formulation contg. (2E)-2-[2-(naphthalen-2-yl)ethoxy]-4-(1-pyrazolylmethyl)cinnamic acid was described.

IT **499144-51-3P 499144-52-4P 499150-74-2P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

RN 499144-51-3 HCAPLUS

CN Benzenepropanoic acid, 4-[(methylphenylamino)methyl]-2-[2-(2-naphthalenyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 499144-52-4 HCAPLUS
CN Benzenepropanoic acid, 4-[(ethylphenylamino)methyl]-2-[2-(2-naphthalenyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 499150-74-2 HCAPLUS
CN Benzenebutanoic acid, 4-[(methylphenylamino)methyl]-2-[[2-(1-naphthalenyl)-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 13 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2002:275954 HCAPLUS
DOCUMENT NUMBER: 136:294653
TITLE: Preparation of aminomethylarylalkanoates as peroxisome proliferator-activated receptor (PPAR-α) activators.
INVENTOR(S): Urbahns, Klaus; Woltering, Michael; Nikolic, Susanne; Pernerstorfer, Josef; Hinzen, Berthold; Dittrich-Wengenroth, Elke; Bischoff, Hilmar; Hirth-Dietrich, Claudia; Lustig, Klemens
PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 156 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002028821	A2	20020411	WO 2001-EP11005	20010924
WO 2002028821	A3	20020815		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10124905	A1	20020411	DE 2001-10124905	20010522
AU 2001093838	A5	20020415	AU 2001-93838	20010924
CA 2424540	AA	20030402	CA 2001-2424540	20010924
BR 2001014437	A	20030701	BR 2001-14437	20010924
EP 1328508	A2	20030723	EP 2001-974287	20010924
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EE 200300140	A	20030815	EE 2003-140	20010924
JP 2004510757	T2	20040408	JP 2002-532408	20010924
NZ 525119	A	20050429	NZ 2001-525119	20010924
US 2003032671	A1	20030213	US 2001-973753	20011009
US 6548538	B2	20030415		
US 2003187041	A1	20031002	US 2003-349448	20030122
US 6750236	B2	20040615		
BG 107684	A	20031031	BG 2003-107684	20030328
NO 2003001517	A	20030528	NO 2003-1517	20030403
ZA 2003002610	A	20040405	ZA 2003-2610	20030403
US 2004176445	A1	20040909	US 2004-797311	20040309

PRIORITY APPLN. INFO.:		
DE 2000-10049208	A	20001005
DE 2001-10124905	A	20010522
WO 2001-EP11005	W	20010924
US 2001-973753	A1	20011009
US 2003-349448	A1	20030122

OTHER SOURCE(S): MARPAT 136:294653
GI



AB Title compds. [I; A = bond, CH2, CH2CH2; X = O, S, CH2; R1-R3 = H, alkyl, cycloalkyl, OH, alkoxy, aryloxy, halo, CF3, OCF3, alkylaminosulfonyl, NO2, cyano; R1R2 = atoms to form a cyclohexane or benzene ring; R4 = H, alkyl; R5, R6 = H; R5R6C = CO; R7 = H, alkyl, (substituted) Ph, PhCH2; R8 = H, (substituted) alkyl, aryl; R8, R9 = H, alkyl, alkoxy, CF3, OCF3, halo; R11, R12 = H, alkyl; R11R12C = cycloalkyl; R13 = H, hydrolyzable group], were prepd. Thus, N-[4-(3-tert-butoxy-2,2-dimethyl-3-oxopropyl)benzyl]-N-(2-furylmethyl)glycine (prepn. given), 2,4-dimethylaniline, 1-hydroxy-1H-benzotriazole, 1-ethyl-3-(3-dimethylamino)propylcarbodiimide

hydrochloride, N-methylmorpholine, and 4-dimethylaminopyridine were stirred in DMF to give 91% tert-butyl-3-[4-[[[2-(2,4-dimethylphenyl)amino-2-oxoethyl](2-furylmethyl)amino]methyl]phenyl]-2,2-dimethylpropionate. Tested I activated PPARα with EC50 = 0.004-200 nM.

IT **409096-04-4P 409096-05-5P 409096-06-6P 409096-07-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of aminomethylarylalkanoates as peroxisome proliferator-activated receptor activators)

RN 409096-04-4 HCAPLUS
CN Benzenepropanoic acid, 4-[[[2-[(2,4-dimethylphenyl)amino]-2-oxoethyl]phenylamino]methyl]-α,α-dimethyl- (9CI) (CA INDEX NAME)



RN 409096-05-5 HCAPLUS
CN Benzenepropanoic acid, 4-[[[2-[(4-methoxy-2,5-dimethylphenyl)amino]-2-oxoethyl]phenylamino]methyl]-α,α-dimethyl- (9CI) (CA INDEX NAME)



RN 409096-06-6 HCAPLUS
CN Benzenepropanoic acid, 4-[[[2-[(2,4-dimethylphenyl)amino]-2-oxoethyl](4-methylphenyl)amino]methyl]-α,α-dimethyl- (9CI) (CA INDEX NAME)



RN 409096-07-7 HCAPLUS
CN Benzenepropanoic acid, 4-[[[2-[(4-methoxy-2,5-dimethylphenyl)amino]-2-oxoethyl](4-methylphenyl)amino]methyl]-α,α-dimethyl- (9CI) (CA INDEX NAME)



L6 ANSWER 14 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2001:693265 HCAPLUS
DOCUMENT NUMBER: 135:242013
TITLE: Preparation of 4-(2-amino-2-carboxyethyl)benzoates as α4β1 and α4β7 integrin inhibitors
INVENTOR(S): Cooke, Nigel Graham; Sabio, Michael Lloyd
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001068586	A2	20010920	WO 2001-EP2749	20010312
WO 2001068586	A3	20020110		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002091142	A1	20020711	US 2001-803303	20010309
PRIORITY APPLN. INFO.:			US 2000-525700 A	20000314
			US 2000-304184P P	20000314

OTHER SOURCE(S): MARPAT 135:242013
GI



AB The title compds. (I) [wherein A = (hetero)arom. ring; Q = bond, CO, alkylene optionally substituted by OH or Ph, alkenylene, or O-alkylene; X = OR5 or NR5R6; R1, R2, and R3 = independently H, halo, OH, alkyl, alkoxy, NO2, NH2, carboxy (amide or ester), CN, alkylcarbonyl, alkylthio, alkylsulfonyl, sulfamoyl, Ph, or heterocyclic; or 2 of R1-R3 together form alkylenedioxy; R4 = H, alkyl(interrupted by 1 or more O), alkenyl, alkynyl, morpholinoalkyl, aminoalkyl, etc.; R5 and R6 = independently H, alkyl optionally substituted by F or (un)substituted (hetero)aryl; with proviso] and their pharmaceutically acceptable salts were prepd. as inhibitors of α4β1 and/or α4β7 integrins. For example, a mixt. of tert-Bu 4-[(S)-2-amino-2-methoxycarbonylethyl]benzoate ?HCl (prepn. given), (S)-3-acetylthiazolidine-4-carboxylic acid, 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide?HCl, 1-hydroxy-7-azabenzotriazole, and di-isopropylethylamine in DMF was stirred at room temp. for 18 h to give II. One or more of the invention compds. was tested for cell adhesion inhibitory activity and exhibited IC 50 values as low as 1 nM for VLA-4 binding. I are useful in inhibiting cell adhesion and in the therapeutic or prophylactic treatment of transplant rejection and inflammatory and autoimmune diseases (no data).

IT **360045-44-9P** **360045-46-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of phenylalanine derivs. as α4β1 and α4β7 integrin inhibitors for treatment of inflammation, transplant rejection, and autoimmune diseases)

RN 360045-44-9 HCAPLUS

CN L-Phenylalanine, N-(2,6-dichlorobenzoyl)-4-[[(2,6-dichlorophenyl)methylamino]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 360045-46-1 HCAPLUS
CN L-Phenylalanine, 4-[[(2-chlorophenyl)methylamino]carbonyl]-N-(2,6-dichlorobenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 15 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN

Full Text | String References

ACCESSION NUMBER: 2000:900630 HCAPLUS
DOCUMENT NUMBER: 134:56698
TITLE: Preparation process and effect of benzazepine derivatives as CCR5 antagonists
INVENTOR(S): Shiraishi, Mitsuru; Baba, Masanori; Aramaki, Yoshio; Kanzaki, Naoyuki; Nishimura, Osamu
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 342 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000076993	A1	20001221	WO 2000-JP3879	20000615
W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6936602	B1	20050830	US 2001-18321	19990616
CA 2380860	AA	20001221	CA 2000-2380860	20000615
EP 1186604	A1	20020313	EP 2000-939065	20000615
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

JP 2001058992	A2	20010306	JP 2000-185904		20000616
PRIORITY APPLN. INFO.:			JP 1999-170345	A	19990616
			WO 2000-JP3879	W	20000615

OTHER SOURCE(S): MARPAT 134:56698
GI



AB Title compds. [I; R1 is a five- or six-membered arom. ring which bears a substituent represented by the general formula: RZ1XZ2; R is hydrogen or optionally substituted hydrocarbyl; X is optionally substituted alkylene; and Z1 and Z2 are each a heteroatom and may be further substituted, with R being optionally bonded to the arom. ring to form another ring; Y is optionally substituted imino; and R2 and R3 are each optionally substituted aliph. hydrocarbyl or an optionally substituted hetero-alicyclic group] and salts, which exhibit CCR5 antagonism and exert preventive and therapeutic effects against HIV infections in mammal. Thus, the title compd. II was prepd.

IT 313755-08-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. process and effect of benzazepine derivs. as CCR5 antagonists)

RN 313755-08-7 HCAPLUS

CN L-Phenylalanine, 4-[[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 16 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN

Full Text | Links References

ACCESSION NUMBER: 1998:259658 HCAPLUS
DOCUMENT NUMBER: 128:294701
TITLE: Preparation of N-bipiperidinylbenzamides and analogs as cell adhesion inhibitors
INVENTOR(S): Pieper, Helmut; Linz, Guenter; Austel, Volkhard; Himmelsbach, Frank; Guth, Brian; Weisenberger, Johannes
PATENT ASSIGNEE(S): Dr. Karl Thomae G.m.b.H., Germany
SOURCE: Ger. Offen., 40 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19643331	A1	19980423	DE 1996-19643331	19961021
WO 9817646	A1	19980430	WO 1997-EP5683	19971015
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9748674	A1	19980515	AU 1997-48674	19971015
PRIORITY APPLN. INFO.:			DE 1996-19643331 A	19961021
			WO 1997-EP5683 W	19971015

OTHER SOURCE(S): MARPAT 128:294701
GI



II

AB RaZNRbABD [I; A = Z1Z2; B = CO, CH2CO, OCH2CO, NHCH2CO, etc.; D = OH, (phenyl)alkoxy, cycloalkyloxy, etc.; Ra = H, (ar)alkyl, metabolically labile group, etc.; Rb = H, (cyclo)alkyl, aryl(alkyl), pyridyl(alkyl), ZRa, etc.; Z = 4,1'-bipiperidine-1,4'-diyl; Z1 = CO, CH2, CONH; Z2 = cyclohexylene, phenylene, etc.] were prepd. Thus, 4-(MeO)C6H4CH2NH2 was reductively condensed with 1-tert-butoxycarbonyl-4-piperidone and the product amidated by 4-(HO2C)C6H4OCH2CO2Me to give, in 3 addnl. steps, title compd. II. Data for biol. activity of I were given.

IT **206273-46-3P 206273-47-4P 206273-48-5P**

206273-49-6P 206273-50-9P 206273-56-5P
206273-59-8P 206273-63-4P 206273-64-5P
206273-65-6P 206273-66-7P 206273-67-8P
206273-74-7P 206273-75-8P 206273-76-9P
206273-77-0P 206273-79-2P 206273-81-6P
206273-82-7P 206273-83-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-bipiperidinylbenzamides and analogs as cell adhesion inhibitors)

RN 206273-46-3 HCAPLUS
CN Acetic acid, [4-[[[1,4'-bipiperidin]-4-yl[(4-methoxyphenyl)methyl]amino]carbonyl]phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



RN 206273-47-4 HCAPLUS
CN [1,4'-Bipiperidine]-1'-carboxylic acid, 4-[[4-(carboxymethoxy)benzoyl][(4-methoxyphenyl)methyl]amino]-, 1'-(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 206273-48-5 HCAPLUS
CN Acetic acid, [4-[[[1,4'-bipiperidin]-4-yl(phenylmethyl)amino]carbonyl]phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



RN 206273-49-6 HCAPLUS
CN Acetic acid, [4-[[[1,4'-bipiperidin]-4-yl(phenylmethyl)amino]methyl]phenox

y]-, trihydrochloride (9CI) (CA INDEX NAME)



RN 206273-50-9 HCAPLUS
CN Acetic acid, [4-[[[1,4'-bipiperidin]-4-yl[(4-methoxyphenyl)methyl]amino]methyl]phenoxy]-, trihydrochloride (9CI) (CA INDEX NAME)



RN 206273-56-5 HCAPLUS
CN Acetic acid, [4-[[[1,4'-bipiperidin]-4-yl(2-methylpropyl)amino]carbonyl]phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



RN 206273-59-8 HCAPLUS
CN Acetic acid, [4-[([1,4'-bipiperidin]-4-ylmethylamino)carbonyl]phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



RN 206273-63-4 HCAPLUS
CN Acetic acid, [4-[[[1,4'-bipiperidin]-4-yl[(4-fluorophenyl)methyl]amino]carbonyl]phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



RN 206273-64-5 HCAPLUS
CN Acetic acid, [4-[[[1,4'-bipiperidin]-4-yl(cyclohexylmethyl)amino]carbonyl]phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



RN 206273-65-6 HCAPLUS
CN Acetic acid, [4-[[[1,4'-bipiperidin]-4-yl(3-pyridinylmethyl)amino]carbonyl]phenoxy]-, trihydrochloride (9CI) (CA INDEX NAME)



RN 206273-66-7 HCAPLUS
CN Acetic acid, [4-[[[1,4'-bipiperidin]-4-yl(4-pyridinylmethyl)amino]carbonyl]phenoxy]-, trihydrochloride (9CI) (CA INDEX NAME)



RN 206273-67-8 HCAPLUS
CN Glycine, N-[1,4'-bipiperidin]-4-yl-N-[4-(carboxymethoxy)benzoyl]-, dihydrochloride (9CI) (CA INDEX NAME)



RN 206273-74-7 HCAPLUS
CN Acetic acid, [4-[[[1,4'-bipiperidin]-4-yl[(4-methoxyphenyl)methyl]amino]carbonyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 206273-75-8 HCAPLUS
CN Acetic acid, [4-[[[1,4'-bipiperidin]-4-yl(phenylmethyl)amino]carbonyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 206273-76-9 HCAPLUS
CN Acetic acid, [4-[[[1,4'-bipiperidin]-4-yl(2-methylpropyl)amino]carbonyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 206273-77-0 HCAPLUS
CN Acetic acid, [4-[[[1,4'-bipiperidin]-4-yl(4-pyridinylmethyl)amino]carbonyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 206273-79-2 HCAPLUS
CN Acetic acid, [4-[[[1,4'-bipiperidin]-4-yl[(4-fluorophenyl)methyl]amino]car bonyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 206273-81-6 HCAPLUS
CN Acetic acid, [4-[[[1,4'-bipiperidin]-4-yl[(4-methoxyphenyl)methyl]amino]me thyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 206273-82-7 HCAPLUS
CN Acetic acid, [4-[[[1,4'-bipiperidin]-4-yl(phenylmethyl)amino]methyl]phenox y]- (9CI) (CA INDEX NAME)



RN 206273-83-8 HCAPLUS

CN Acetic acid, [4-[[[1,4'-bipiperidin]-4-yl(3-pyridinylmethyl)amino]carbonyl]phenoxy]- (9CI) (CA INDEX NAME)



L6 ANSWER 17 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN

Full Text | More References

ACCESSION NUMBER: 1998:163568 HCAPLUS
DOCUMENT NUMBER: 128:204814
TITLE: Preparation of quinoline moiety-containing benzenesulfone derivatives as leukotriene and thromboxane A2 antagonists
INVENTOR(S): Yokota, Masaki; Kawazoe, Souichirou; Okamoto, Yoshinori; Kubota, Hirokazu; Naito, Ryo; Arakida, Yasuhito
PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 116 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9808820	A1	19980305	WO 1997-JP2934	19970825
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9738684	A1	19980319	AU 1997-38684	19970825
PRIORITY APPLN. INFO.:			JP 1996-224236 A	19960826
			WO 1997-JP2934 W	19970825

OTHER SOURCE(S): MARPAT 128:204814
GI



AB The title compds. I [ring B represents an optionally substituted quinolyl group;ring D represents an optionally substituted Ph group; E represents CHX, etc.; one of A1 and A2 represents an optionally substituted methylene group or an optionally substituted ethylene group with the other representing a single bond, an optionally substituted methylene group, or an optionally substituted ethylene group; a proviso is given; X represents an oxygen atom or a sulfur atom; Y represents an optionally substituted phenylene group, an optionally substituted phenyleneoxy group, etc.; Z represents CH:CH, CH2CH2, CH2O, or OCH2; R represents a carboxyl group or tetrazolyl group which may be optionally substituted with an ester residue; p, n are each 0 or 1; and m represents 1, 2, or 3] are prepd. I are useful in the treatment of asthma. In an in vitro test for inhibiting activity against the contraction of guinea pig ileum induced by leukotriene D4 (LTD4) (10-9 M), the title compd. II showed IC50 of 0.00036 μM. In an in vitro test for inhibition of platelet aggregation induced by U-46619 (thromboxane A2 analog) (10-6 M), II showed IC50 of 0.45 μM.

IT **203939-99-5P** **203940-02-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of quinoline moiety-contg. benzenesulfone derivs. as leukotriene and thromboxane A2 antagonists)

RN 203939-99-5 HCAPLUS

CN Acetic acid, [4-[[[[[(4-chlorophenyl)sulfonyl]amino]acetyl][3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]amino]methyl]phenoxy]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 203940-02-7 HCAPLUS

CN Benzenepropanoic acid, 4-[[[[[(4-chlorophenyl)sulfonyl]amino]acetyl][3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]amino]methyl]-, (E)- (9CI) (CA

INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 18 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1995:330551 HCAPLUS
DOCUMENT NUMBER: 122:108666
TITLE: Acridinium oligonucleotide probes, their preparation and use.
INVENTOR(S): Skrzipczyk, Heinz Juergen; Uhlmann, Eugen; Mayer, Andreas
PATENT ASSIGNEE(S): Hoechst A.-G., Germany
SOURCE: Eur. Pat. Appl., 69 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 602524	A1	19940622	EP 1993-119783	19931208
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
FI 9305579	A	19940616	FI 1993-5579	19931213
CA 2111384	AA	19940616	CA 1993-2111384	19931214
JP 06209798	A2	19940802	JP 1993-342076	19931214
PRIORITY APPLN. INFO.:			DE 1992-4242202 A	19921215

GI



AB Acridinium compds. (I; R1 = H, hydrocarbyl; R2, R3 = H, alkyl, amino, alkoxy, cyano, carboxy, nitro, halo; R4 = nucleotide-attaching sulfonamido group; A- = anion, such as SO3F-, F3CCO2-) are obtained for chemiluminescence labeling of oligonucleotides in immunoassay. Thus, benzyl 4-(N-phenylsulfonamido)benzoate was condensed with 9-acridinecarboxylic acid chloride hydrochloride to give an acridinecarboxamide, which was debenzylated with HBr and the resulting acid hydrobromide was esterified with N-hydroxysuccinimide. The ensuing

succinimidyloxy ester could then be converted to the trifluoroacetate or fluorosulfate salt for use as a label.

IT 125603-07-8P 125603-20-5P 125603-26-1P
160680-01-3P 160680-12-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; acridinium probes for chemiluminescent labeling of oligonucleotides)

RN 125603-07-8 HCAPLUS
CN Benzenepropanoic acid, 4-[[(9-acridinylcarbonyl)(4-methoxyphenyl)amino]sulfonyl]-, monohydrobromide (9CI) (CA INDEX NAME)



RN 125603-20-5 HCAPLUS
CN Benzenepropanoic acid, 4-[[(9-acridinylcarbonyl)(2,4-dimethoxyphenyl)amino]sulfonyl]-, monohydrobromide (9CI) (CA INDEX NAME)



RN 125603-26-1 HCAPLUS
CN Benzenepropanoic acid, 4-[[(9-acridinylcarbonyl)(2,3-dihydro-1,4-benzodioxin-6-yl)amino]sulfonyl]-, monohydrobromide (9CI) (CA INDEX NAME)



\# HBr

RN 160680-01-3 HCAPLUS

CN Benzenepropanoic acid, 4-[[(9-acridinylcarbonyl)[4-[2-(4-morpholinyl)ethoxy]phenyl]amino]sulfonyl]- (9CI) (CA INDEX NAME)





RN 160680-12-6 HCAPLUS

CN Benzenepropanoic acid, 4-[[(9-acridinylcarbonyl)[4-[2-[2-(2-ethoxyethoxy)ethoxy]ethoxy]phenyl]amino]sulfonyl]-, monohydrobromide (9CI) (CA INDEX NAME)



L6 ANSWER 19 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1995:261300 HCAPLUS
DOCUMENT NUMBER: 122:105894
TITLE: Preparation of (tetrazolyl)heterocyclyl-substituted benzylaminopyridine angiotensin II receptor antagonists
INVENTOR(S): De, Biswanath
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: U.S., 46 pp. Cont.-in-part of U.S. Ser. No. 848,618, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 5364869	A	19941115	US 1993-1472		19930107
PRIORITY APPLN. INFO.:			US 1993-1472	B2	19930107
			US 1992-848618		19920309

OTHER SOURCE(S): MARPAT 122:105894
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; R3 = H, lower alkyl, halogen, alkoxy; R4 = CO2R7; R7 = H, carboxy-protecting group; R5 = H, (un)substituted lower alkyl, alkenyl, alkynyl, cycloalkyl, etc.; R6 = H, lower alkyl, halogen] [e.g., 4-[N-propyl-N-[[3-bromo-2-[2-(1H-tetrazol-5-yl)phenyl]benzo[6]thiophenyl-6-yl]methyl]amino]pyridine-3-carboxylic acid (sic)], useful as angiotensin II receptor antagonists for the treatment of hypertension (no data) and congestive heart failure (no data), are prepd.

IT **160590-42-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of (tetrazolyl)heterocyclyl-substituted benzylaminopyridine angiotensin II receptor antagonists)

RN 160590-42-1 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[[[4-(carboxyphenylmethoxy)phenyl]methyl]propylamino]-2-methyl- (9CI) (CA INDEX NAME)



L6 ANSWER 20 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1992:214505 HCAPLUS
DOCUMENT NUMBER: 116:214505
TITLE: Preparation and formulation of tetrazole derivatives as antiallergic and antiinflammatory agents
INVENTOR(S): Yoshimoto, Yoshihiko; Yasufuku, Shoji; Makita, Yoshihiko; Inoue, Kichiro; Nakanouchi, Kei
PATENT ASSIGNEE(S): Nippon Shinyaku Co., Ltd., Japan
SOURCE: PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9200285	A1	19920109	WO 1991-JP830	19910620
W: AU, BR, CA, FI, HU, JP, KR, NO, SU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
JP 04297466	A2	19921021	JP 1991-89623	19910327
CA 2086117	AA	19911223	CA 1991-2086117	19910620
AU 9180661	A1	19920123	AU 1991-80661	19910620
AU 645101	B2	19940106		
EP 536400	A1	19930414	EP 1991-910848	19910620
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
BR 9106582	A	19930601	BR 1991-6582	19910620
HU 65633	A2	19940728	HU 1992-4072	19910620
JP 2591345	B2	19970319	JP 1991-510766	19910620
RU 2115648	C1	19980720	RU 1992-16567	19910620
CN 1063687	A	19920819	CN 1991-111206	19911125
CN 1037681	B	19980311		
NO 9204947	A	19930219	NO 1992-4947	19921221
US 5399703	A	19950321	US 1993-966022	19930204

PRIORITY APPLN. INFO.:

JP 1990-165067	A	19900622
JP 1991-32327	A	19910131
JP 1991-89623	A	19910327
WO 1991-JP830	A	19910620

OTHER SOURCE(S): MARPAT 116:214505
GI



AB Tetrazole derivs. [I; A = (O)m(CHR4)n (wherein R4 = H, alkyl; m, n = 0, 1); B = O, S(O)p (wherein p = 0-2); R1 = H, alkyl, alkoxy, halo, etc.; R2 = (substituted) alkyl, alkenyl, aralkyl; R3 = H, alkoxy, halo; R9 = H, alkoxy, alkyl, acyloxy, halo, NO2, OH; R10 = H, alkyl], useful in treating bronchial asthma and allergic rhinitis, are prepd. A soln. of amine 2.1 g amine II and Et3N in CH2Cl was stirred with a soln. of 1.7 g 4-(hexyloxy)benzoyl chloride in C6H6, and the soln. was refluxed to give 2.2 g amide III. Also prepd. were 134 addnl. I, which showed LTD4 binding inhibition with IC50 as low as 3.58 8-10 ıM, vs. 3.82 6-10 ıM with FPL-55712. Tablet and granule formulations were given.

IT **140426-93-3P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as antiallergic and antiinflammatory agent)

RN 140426-93-3 HCAPLUS

CN Acetic acid, [4-[[methyl[2-[[2-(1H-tetrazol-5-yl)phenyl]thio]phenyl]amino]carbonyl]phenoxy]- (9CI) (CA INDEX NAME)



L6 ANSWER 21 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1990:141241 HCAPLUS
DOCUMENT NUMBER: 112:141241
TITLE: Reactive acridinium dyes for chemiluminescent immunoassays
INVENTOR(S): Kinkel, Tonio; Molz, Peter; Schmidt, Erwin; Schnorr,

Gerd; Skrzipczyk, Heinz Juergen
PATENT ASSIGNEE(S): Hoechst A.-G., Fed. Rep. Ger.
SOURCE: Ger. Offen., 19 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3805318	A1	19890831	DE 1988-3805318	19880220
DE 3805318	C2	19980723		
DE 3844954	C2	19980716	DE 1988-3844954	19880220
EP 330050	A2	19890830	EP 1989-102487	19890214
EP 330050	A3	19911106		
EP 330050	B1	20000823		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AT 195757	E	20000915	AT 1989-102487	19890214
ES 2151474	T3	20010101	ES 1989-102487	19890214
FI 8900754	A	19890821	FI 1989-754	19890216
FI 90537	B	19931115		
FI 90537	C	19940225		
DK 8900742	A	19890821	DK 1989-742	19890217
DK 175493	B1	20041108		
NO 8900689	A	19890821	NO 1989-689	19890217
NO 173237	B	19930809		
NO 173237	C	19931117		
JP 01261461	A2	19891018	JP 1989-36428	19890217
CA 1339390	A1	19970826	CA 1989-591436	19890217
NO 9203800	A	19890821	NO 1992-3800	19920930
NO 303657	B1	19980810		
DK 9300307	A	19930318	DK 1993-307	19930318
DK 173972	B1	20020318		
US 6002007	A	19991214	US 1993-93694	19930720
US 5783696	A	19980721	US 1995-474552	19950607
US 5879953	A	19990309	US 1995-479196	19950607
GR 3034888	T3	20010228	GR 2000-402577	20001122

PRIORITY APPLN. INFO.:

DE 1988-3805318	A3	19880220
NO 1989-689	A1	19890217
US 1989-311912	B1	19890217
US 1993-93694	A3	19930720

OTHER SOURCE(S): CASREACT 112:141241
GI



I

AB The title dyes I [A = anion; R1 = H, C1-10 alkyl, alkenyl, alkynyl, PhCH2, aryl; R2, R3 = H, C1-4 alkyl, (un)substituted amino, CO2H, alkoxy, CN, NO2, halogen; R4 = R6NSO2Xr5, R5XNSO2R6; R5 = a substituent which is selectively reactive to biol. bound amino or thiol or carboxy groups; R6 = H, alkyl, alkenyl, C1-10 alkoxy, substituted amino, PhCH2, aryl, heteroaryl, (un)substituted heterocyclic residue; X = divalent arylene

group, direct bond, divalent alkylene group, divalent oxyalkyl groups, S, N], which react with antibodies to form dye-labeled antibodies which are used in chemiluminescent immunoassay procedures, are prepd. Thus, 4'-[N-(4-methoxyphenyl)sulfamido]-3-phenylpropionic acid benzyl ester reacted with 9-acridinecarboxylic acid chloride hydrochloride, the intermediate reacted with HBr in AcOH, the intermediate reacted with chloroformic acid Et ester and N-hydroxysuccinimide, and the intermediate reacted with Me fluorosulfonate, producing N-(4-methoxyphenyl)-N-[4-(2-succinimidoyloxycarbonylethyl)benzenesulfonyl]-10-methylacridinium-9-carboxylic acid amide fluorosulfonate (I). I was conjugated with a TSH antibody and the I-antibody conjugate used in a TSH chemiluminescent immunoassay.

IT **125603-26-1P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and reaction of)

RN 125603-26-1 HCAPLUS

CN Benzenepropanoic acid, 4-[[(9-acridinylcarbonyl)(2,3-dihydro-1,4-benzodioxin-6-yl)amino]sulfonyl]-, monohydrobromide (9CI) (CA INDEX NAME)



IT **125603-20-5P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and reaction of, in chemiluminescent reactive dye manuf.)

RN 125603-20-5 HCAPLUS

CN Benzenepropanoic acid, 4-[[(9-acridinylcarbonyl)(2,4-dimethoxyphenyl)amino]sulfonyl]-, monohydrobromide (9CI) (CA INDEX NAME)



IT **125603-07-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction of, with chloroformic acid Et ester and hydroxysuccinimide)
RN 125603-07-8 HCAPLUS
CN Benzenepropanoic acid, 4-[[(9-acridinylcarbonyl)(4-methoxyphenyl)amino]sulfonyl]-, monohydrobromide (9CI) (CA INDEX NAME)



L6 ANSWER 22 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN

Full Text | Citing References

ACCESSION NUMBER:	1981:461738 HCAPLUS
DOCUMENT NUMBER:	95:61738
TITLE:	Substituted-phenyl substituted-alkyl ethers
INVENTOR(S):	Kamiya, Takashi; Saito, Yoshihisa
PATENT ASSIGNEE(S):	Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE:	U.S., 21 pp. Cont.-in-part of U.S. Ser. No. 583,474, abandoned. CODEN: USXXAM
DOCUMENT TYPE:	Patent
LANGUAGE:	English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4214094	A	19800722	US 1977-782967	19770330
PRIORITY APPLN. INFO.:			US 1975-583474 A2	19750603

GI



AB Title compds. I (R = H, OH, alkoxy; R1 = aryl, aralkyl; R2 = H, alkyl, aryl, aralkyl; R3 = alkyl, R4 = H, alkyl; R5 = CO2H, alkoxycarbonyl; Z = alkylene) were prepd. as hypolipemics (no data). Thus, phenol II was treated with Me2CBrCO2Et in MeCOCH2CHMe2 contg. K2CO3 under reflux for 6 h to give phenl ether III.

IT **58336-67-7P 58336-68-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 58336-67-7 HCAPLUS
CN Propanoic acid, 2-[4-[[(4-chlorophenyl)methylamino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



102 b

RN 58336-68-8 HCAPLUS
CN Propanoic acid, 2-[4-[[(4-chlorophenyl)(phenylmethyl)amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



L6 ANSWER 23 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN

Full Text | Citing References

ACCESSION NUMBER:	1981:65461 HCAPLUS
DOCUMENT NUMBER:	94:65461
TITLE:	4-Unsubstituted azetidinone derivatives
INVENTOR(S):	Hashimoto, Masashi; Hemmi, Keiji; Kamiya, Takashi; Komori, Tadaaki; Nakaguti, Osamu; Saito, Yoshihisa;

Nocardia) was identified as I, 543 analogs [II; R = NH2 or acylamino; R1 = alkyl (satd. or unsatd., straight-chain or branched) with substituents, e.g., CO2H (or its derivs.), CN, OH, NH2, Ph or substituted Ph] were prepd. by std. procedures and shown to be effective against, e.g., Bacillus subtilis, Escherichia coli, and Staphylococcus aureus.

IT **59510-89-3**
RL: RCT (Reactant); RACT (Reactant or reagent)
(acylation by, of aminolactacillanic acid)

RN 59510-89-3 HCAPLUS

CN Propanoic acid, 2-[4-[[(4-chlorophenyl)[(2,2,2-trichloroethoxy)carbonyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



L6 ANSWER 27 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN

Full Text | More References

ACCESSION NUMBER: 1976:73931 HCAPLUS
DOCUMENT NUMBER: 84:73931
TITLE: Phenyl-substituted alkyl ethers
INVENTOR(S): Kamiya, Takashi; Saito, Yoshihisa
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: Ger. Offen., 86 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2524865	A1	19760102	DE 1975-2524865	19750604
JP 50154214	A2	19751212	JP 1974-63658	19740604
JP 59003465	B4	19840124		
JP 50157325	A2	19751219	JP 1974-66274	19740610
JP 59003466	B4	19840124		
JP 50157326	A2	19751219	JP 1974-66275	19740610
JP 51125229	A2	19761101	JP 1975-15775	19750205
JP 59029575	B4	19840721		
JP 51125230	A2	19761101	JP 1975-15938	19750206
JP 59029576	B4	19840721		
JP 51100033	A2	19760903	JP 1975-26327	19750303
JP 59029577	B4	19840721		
JP 51101938	A2	19760908	JP 1975-26796	19750304
JP 59029578	B4	19840721		
JP 51101977	A2	19760908	JP 1975-27869	19750306
JP 60025425	B4	19850618		
JP 51101939	A2	19760908	JP 1975-27870	19750306
JP 59029579	B4	19840721		
JP 51105022	A2	19760917	JP 1975-28376	19750308
JP 59029580	B4	19840721		

```
     FILE 'REGISTRY' ENTERED AT 01:40:40 ON 06 FEB 2006
L1              STRUCTURE UPLOADED
L2            0 S L1
L3          186 S L1 FULL

     FILE 'HCAPLUS' ENTERED AT 01:47:01 ON 06 FEB 2006
L4           30 S L3
L5            1 S L4 AND BESWICK, P?/AU
L6           29 S L4 NOT L5
L7            0 S L6 AND HARLING, J?/AU
L8            0 S L6 AND KLEANTHOUS, S?/AU
L9            0 S L6 AND LAMBERT, M?/AU
L10           0 S L6 AND PATEL, V?/AU
L11           0 S L6 AND SIMPSON, J?/AU

     FILE 'CAOLD' ENTERED AT 01:49:56 ON 06 FEB 2006

=> s l3
L12           1 L3

=> d l12, all, 1

L12  ANSWER 1 OF 1  CAOLD  COPYRIGHT 2006 ACS on STN
AN   CA55:5848h  CAOLD
TI   org. compds. and their biol. activity - (II)
AU   Stavric, B.; Cerkovnikov, E.
IT  99987-21-0 100796-33-6 108922-34-5 114617-87-7 119300-85-5 119301-71-2
     120971-95-1


=> fil reg; d acc 108922-34-5; fil CAOLD

FILE 'REGISTRY' ENTERED AT 01:50:18 ON 06 FEB 2006


ANSWER 1  REGISTRY  COPYRIGHT 2006 ACS on STN
RN   108922-34-5  REGISTRY
ED   Entered STN:  03 Jul 1987
CN   Glycine, N-[p-(carboxymethoxy)phenylsulfonyl]-N-2-thiazolyl-, disodium
     salt (6CI)  (CA INDEX NAME)
MF   C13 H12 N2 O7 S2 . 2 Na
SR   CAOLD
LC   STN Files:   CA, CAOLD, CAPLUS
CRN  (807269-04-1)
```




```
                1 REFERENCES IN FILE CA (1907 TO DATE)
                1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
                1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)
```

FILE 'CAOLD' ENTERED AT 01:50:18 ON 06 FEB 2006

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.44	341.39

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-22.50

FILE 'HCAPLUS' ENTERED AT 01:50:25 ON 06 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 6 Feb 2006 VOL 144 ISS 7
FILE LAST UPDATED: 5 Feb 2006 (20060205/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance





* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	DEC 05	CASREACT(R) - Over 10 million reactions available
NEWS 4	DEC 14	2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS 5	DEC 14	2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS 6	DEC 14	CA/CAplus to be enhanced with updated IPC codes
NEWS 7	DEC 21	IPC search and display fields enhanced in CA/CAplus with the IPC reform
NEWS 8	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/ USPAT2
NEWS 9	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 10	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS 11	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS 12	JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS 13	JAN 30	Saved answer limit increased
NEWS 14	JAN 31	Monthly current-awareness alert (SDI) frequency added to TULSA

NEWS EXPRESS JANUARY 03 CURRENT VERSION FOR WINDOWS IS V8.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT http://download.cas.org/express/v8.0-Discover/

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 01:59:00 ON 06 FEB 2006

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 01:59:12 ON 06 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 3 FEB 2006 HIGHEST RN 873528-70-2
DICTIONARY FILE UPDATES: 3 FEB 2006 HIGHEST RN 873528-70-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading structure

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Page 1-A



Page 1-C



Page 1-D



Page 2-C



Page 2-D

C

Page 3-B



Page 3-C

Page 3-D

```
VAR G2=15-14 15-20/16-14 16-20/17-14 17-20
VAR G3=32/22
REP G20=(1-2) 8-2 8-11
NODE ATTRIBUTES:
HCOUNT  IS M1     AT   1
HCOUNT  IS M2     AT   4
HCOUNT  IS M2     AT   5
HCOUNT  IS M2     AT   6
HCOUNT  IS M2     AT  15
NSPEC   IS C      AT   1
NSPEC   IS C      AT   2
NSPEC   IS C      AT   3
NSPEC   IS C      AT   4
NSPEC   IS C      AT   5
NSPEC   IS C      AT   6
NSPEC   IS C      AT   7
NSPEC   IS C      AT   8
NSPEC   IS R      AT   9
NSPEC   IS R      AT  10
NSPEC   IS R      AT  11
NSPEC   IS R      AT  12
NSPEC   IS R      AT  13
NSPEC   IS R      AT  14
NSPEC   IS C      AT  15
NSPEC   IS C      AT  16
NSPEC   IS C      AT  17
NSPEC   IS C      AT  18
NSPEC   IS C      AT  19
NSPEC   IS C      AT  20
NSPEC   IS C      AT  21
NSPEC   IS R      AT  22
NSPEC   IS R      AT  23
NSPEC   IS R      AT  24
NSPEC   IS R      AT  25
```

```
NSPEC   IS R      AT  26
NSPEC   IS R      AT  27
NSPEC   IS C      AT  28
NSPEC   IS C      AT  29
NSPEC   IS C      AT  30
NSPEC   IS C      AT  31
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS  AT   1  2  3  4  5  6  7  8 15 16 17 18 20 21 30 31 32
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC I
NUMBER OF NODES IS  32

STEREO ATTRIBUTES: NONE


=> s l1
SAMPLE SEARCH INITIATED 02:01:16 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    16837 TO ITERATE

 11.9% PROCESSED     2000 ITERATIONS                                0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       328970 TO   344510
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> s l1 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 166.50 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 02:01:21 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   334089 TO ITERATE

 98.3% PROCESSED   328438 ITERATIONS                                8 ANSWERS

100.0% PROCESSED   334089 ITERATIONS                                8 ANSWERS
SEARCH TIME: 00.00.22

L3            8 SEA SSS FUL L1

=> file hcaplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                             168.26     168.47

FILE 'HCAPLUS' ENTERED AT 02:01:47 ON 06 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 6 Feb 2006 VOL 144 ISS 7
FILE LAST UPDATED: 5 Feb 2006 (20060205/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 4 L3

=> d l4, ibib abs hitstr, 1-4

L4 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN

Full Text | More References

ACCESSION NUMBER: 2005:238962 HCAPLUS
DOCUMENT NUMBER: 142:316838
TITLE: Preparation of azole compounds as PPARα agonists
INVENTOR(S): Yamazaki, Yukiyoshi; Toma, Tsutomu; Nishikawa, Masahiro; Ozawa, Hidefumi; Okuda, Ayumu; Araki, Takaaki; Abe, Kazutoyo; Oda, Soichi
PATENT ASSIGNEE(S): Kowa Co., Ltd., Japan
SOURCE: PCT Int. Appl., 184 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005023777	A1	20050317	WO 2004-JP12750		20040902
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 2005101636	A1	20050512	US 2004-933467		20040903
PRIORITY APPLN. INFO.:			US 2003-499357P	P	20030903
			JP 2003-317353	A	20030909
			JP 2003-364817	A	20031024

OTHER SOURCE(S): MARPAT 142:316838
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1, R2 = H, Me, ethyl; R3a, R3b, R4a, R4b = H, halo, nitro, etc.; Y = carbonyl, carbonylamino, aminocarbonyl, etc.; X = O, S, NR5; R5 = H, alkyl, alkylsulfonyl, etc.; Z = CH, N; n = 1-6; m = 2-6] were prepd. Thus, compd. II was prepd. from 2-iodophenylisothiocyanate in a multistep process. In PPARα (peroxisome proliferator-activated receptor α) activation assays, the EC50 value of compd. II was 0.001 μM. Compds. I are claimed useful for the treatment of hyperlipidemia, arteriosclerosis, etc.

IT **848258-23-1P**

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of azole compds. as PPARα agonists for treatment of hyperlipidemia, arteriosclerosis, etc.)

RN 848258-23-1 HCAPLUS

CN Benzenepropanoic acid, 4-[[2-benzoxazolyl[3-[4-[(methylsulfonyl)oxy]phenoxy]propyl]amino]methyl]-α,α-dimethyl- (9CI) (CA INDEX NAME)



IT **848258-24-2P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of azole compds. as PPARα agonists for treatment of hyperlipidemia, arteriosclerosis, etc.)

RN 848258-24-2 HCAPLUS

CN Benzenepropanoic acid, 4-[[2-benzoxazolyl[3-[4-[(methylsulfonyl)oxy]phenoxy]propyl]amino]methyl]-α,α-dimethyl-, sodium salt (9CI) (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2004:565187 HCAPLUS
DOCUMENT NUMBER: 141:123486
TITLE: Preparation of naphthalene derivatives as selective estrogen receptor modulators
INVENTOR(S): Hamaoka, Shinichi; Kitazawa, Noritaka; Nara, Kazumasa; Sasaki, Atsushi; Kamada, Atsushi; Okabe, Tadashi
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
SOURCE: PCT Int. Appl., 982 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058682	A1	20040715	WO 2003-JP16808	20031225
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2512000	AA	20040715	CA 2003-2512000	20031225
EP 1577288	A1	20050921	EP 2003-782904	20031225
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.: JP 2002-378729 A 20021226
WO 2003-JP16808 W 20031225

OTHER SOURCE(S): MARPAT 141:123486
GI



AB The title compds. I [wherein T = a single bond, (un)substituted alkylene, alkenylene, or alkynylene; A = a single bond, (un)substituted heterocycle, (hetero)arylene, or cyclohydrocarbyl; Y = a single bond, O, S, etc.; Z = CH2O, O, S, etc.; ring G = (hetero)arylene, heterocycle, etc.; Q1 and Q2 = independently N or C; Ra and Rb = independently H, (un)substituted alkyl, alkenyl, alkynyl, etc.; W = a single bond, CO, (un)substituted alkylene, NH, etc.; R' = H, O, S, etc.; R'' = H, OH, halo, etc.; R = H, OH, halo, etc.; L = a single bond, (un)substituted alkylene, alkenylene, or alkynylene] or salts, or hydrates thereof are prepd. as selective estrogen receptor modulators. For example, the compd. II was prepd. in a multi-step synthesis. I showed affinity towards estrogen receptor with Ki of 0.2 to 94 nM in cow.

IT 722538-26-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of naphthalene derivs. as selective estrogen receptor modulators)

RN 722538-26-3 HCAPLUS

CN Benzeneacetic acid, 4-[[[2-[(2R)-6-(2,2-dimethyl-1-oxopropoxy)-1,2,3,4-tetrahydro-2-naphthalenyl]-5-methoxyphenyl](2-ethoxy-2-oxoethyl)amino]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2003:154382 HCAPLUS
DOCUMENT NUMBER: 138:187795
TITLE: Preparation of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivatives as antagonists of prostaglandin E2 (PEG2) receptors
INVENTOR(S): Tani, Kousuke; Asada, Masaki; Kobayashi, Kaoru; Narita, Masami; Ogawa, Mikio

PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 1009 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003016254	A1	20030227	WO 2002-JP8120	20020808
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2457468	AA	20030227	CA 2002-2457468	20020808
EP 1431267	A1	20040623	EP 2002-755874	20020808
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002011810	A	20040824	BR 2002-11810	20020808
CN 1551866	A	20041201	CN 2002-817376	20020808
ZA 2004000973	A	20050104	ZA 2004-973	20040205
NO 2004000564	A	20040510	NO 2004-564	20040206
PRIORITY APPLN. INFO.:			JP 2001-241867 A	20010809
			WO 2002-JP8120 W	20020808

OTHER SOURCE(S): MARPAT 138:187795
GI



AB Carboxylic acid derivs. (I) and nontoxic salts thereof [wherein R1 = CO2H, CO2R4, CH2OH, COR5SO2R6, CONH2, CH2NR5SO2R6, CH2NR9COR10, CH2NR9CONR5SO2R6, CH2SO2NR9COR10, CH2O2CNR5SO2R6, tetrazole, 1,2,4-oxadiazol-5-one, 1,2,4-oxadiazol-5-thione, 1,2,4-thiadiazol-5-one, etc. (wherein R4 = C1-6 alkyl, hydroxy-C1-4 alkyl, C1-4 alkoxy-C1-4 alkyl, carboxy-C1-4 alkyl, etc.; R5, R9 = H, C1-6 alkyl; R6 = C1-6 alkyl, C3-15 mono-, di-, or tricarbocyclic, 3- to 13-membered mono-, di-, or tricyclic heterocyclyl, etc.; R10 = H, R6); A = a single bond, C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, etc.; the ring B = C3-12 mono- or dicyclic carbocyclic ring, 3- to 12-membered mono- or dicyclic heterocyclic ring; R2 = C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C2-6 alkenyl, C2-6 alkynyl, halo, CHF2, CF3, NO2, cyano, Ph, oxo; m, n = 0,1,2; Q = (C1-4 alkylene, C2-4 alkenylene, or C2-4 alkynylene)-Cyc2, -C1-4 alkylene-Z-Cyc3, amino-C1-4 alkyl, cyano-C1-4 alkyl, acylamino-C1-4 alkyl, 3- to 7-membered monocyclic carbocyclyl, 3- to 6-membered monocyclic heterocyclyl, etc. (wherein Cyc2, Cyc3 = C3-15 mono-, di-, or tricyclic carbocyclyl or heterocyclyl, etc.; Z = O, S, SO, SO2, NH, NHCO, etc.); D = an linking chain consisting of 1-2 or 3-6 of atoms selected from C, N, O, or S, etc.; R3 = C1-6 alkyl, C3-15 mono-, di-, or tricyclic carbocyclyl, 3- to

15-membered mono-, di-, or tricyclic heterocyclyl, etc.] are prepd. These carboxylic acid derivs. include phenylpropanoic acid, phenylpropenoic acid, phenylpropanamide, phenylpropenamide, 3-oxoisoindolin-1-ylacetic acid, benzylbenzoic acid, benzylaminoacetic acid, pyrazolylmethylbenzoic acid, benzoylaminoacetic acid, (pyrazolylmethylphenyl)propenoic acid, pyrazolylmethylpropanoic acid, (pyridinyloxyphenyl)propanoic acid, phenoxyacetic acid, phenylbutanoic acid, (pyrazolylmethyl)propanamide, (piperazinylmethylphenyl)propanamide, (morpholinylmethylphenyl)propanamide , (pyridinyloxyphenyl)propanamide, (pyrazolylmethyl)propenamide (oxoimidazolidinylmethylphenyl)propanamide, (oxopyrrolidinylmethylphenyl)p ropenamide, (thiophenylmethylphenyl)propenamide, (pyrazolylmethylphenylamino)acetamide, (thiazolylaminomethylphenyl)propana mide, thiophenylpropenamide, (pyrazolylmethylphenoxy)acetamide, (phenoxymethyl)benzamide, (pyrazolylmethylphenylethyl)-1,2,4-oxadiazol-5-one, and (pyrazolylmethylphenylindolyl)acetic acid. Because of binding to PEG2 receptors, in particular, subtype EP3 and/or subtype EP4 and having antagonism, the compds. I are useful in preventing and/or treating diseases such as pain, allodynia, hyperalgesia, pruritus (itching), urticaria, atopic dermatitis, contact dermatitis, Urushi (Japanese lacquer tree) dermatitis, allergic conjunctivitis, symptoms during dialysis, asthma, rhinitis, allergic rhinitis, nasal congestion, sneeze, psoriasis, pollakiuria (increased urinary frequency), urination disorder, ejaculation (semination) disorder, fever (pyrexia), systemic inflammation reaction, learning disorder, Alzheimer's disease, neovascularization, cancer formation, cancer proliferation, cancer metastasis to organs, cancer metastasis to bone, hypercalcemia accompanied by cancer metastasis to bone, retinopathy, rubrum, erythema (rash), leucoma, skin moth-patch, heat burn, burn, steroid burn, kidney failure, nephropathy, acute or chronic nephritis, blood electrolyte disorder, imminent abortion, threatened abortion, excessive menstruation, dysmenorrhea, endometriosis, premenstrual syndrome, uterine gland myopathy, reprodn. disorder, and stress. They are also useful in preventing and/or treating anxiety, depression, psychophysiol. disorder, mental retardation, thrombus, embolism, transient ischemic attack, cerebral infarction, atheroma, organ transplant, heart failure, hypertension, myocardial infarction, arteriosclerosis, circulation disorders or ulcers assocd. therewith, nerve disorders, vascular dementia, edema, diarrhea, constipation, biliary excretion disorder, ulcerative colitis, Crohn's disease, irritable bowel syndrome, redn. of rebound after using steroid drugs, aids for decreasing or removing steroid drugs, bone diseases, systemic granuloma, immune diseases, pyorrhea alveolaris, gingivitis, periodontal disease, nerve cell death, lung disorder, liver disorder, acute hepatitis, myocardial ischemia, Kawasaki disease, multiple organ failure, chronic headache, angiitis, venous failure, varicose vein (varicosis), anal fistula, diabetes insipidus, neonatal patent ductus arteriosus, and cholelithiasis. Thus, 4-hydroxymethyl-2-[2-(naphthalen-2-yl)ethoxy]cinnamic acid Et ester was mesylated by methanesulfonyl chloride in the presence of Et3N in THF at 0? for 15 min and condensed with pyrazole in the presence of NaH in DMF at 0? to give 2-[2-(naphthalen-2-yl)ethoxy]-4-(1-pyrazolylmethyl)cinnamic acid Et ester. 4-[2-[[2-(Naphthalen-1-yl)propanoyl]amino]-4-methylthiomethylphenyl]butanoic acid inhibited the binding of [3H]PGE2 to prostaglandin E2 (PEG2) receptor subtype EP1, Ep2, EP3, and EP4 expressed in CHO cells with Ki of >10, >10, 0.27, and 0.038 μM, resp. A tablet formulation contg. (2E)-2-[2-(naphthalen-2-yl)ethoxy]-4-(1-pyrazolylmethyl)cinnamic acid was described.

IT **499144-05-7P** **499144-06-8P** **499144-52-4P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic

acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

RN 499144-05-7 HCAPLUS

CN 2-Propenoic acid, 3-[4-[[(methylsulfonyl)phenylamino]methyl]-2-[2-(2-naphthalenyl)ethoxy]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 499144-06-8 HCAPLUS

CN 2-Propenoic acid, 3-[4-[(acetylphenylamino)methyl]-2-[2-(2-naphthalenyl)ethoxy]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 499144-52-4 HCAPLUS

CN Benzenepropanoic acid, 4-[(ethylphenylamino)methyl]-2-[2-(2-naphthalenyl)ethoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1995:330551 HCAPLUS

DOCUMENT NUMBER: 122:108666

TITLE: Acridinium oligonucleotide probes, their preparation and use.

INVENTOR(S): Skrzipczyk, Heinz Juergen; Uhlmann, Eugen; Mayer, Andreas

PATENT ASSIGNEE(S): Hoechst A.-G., Germany

SOURCE: Eur. Pat. Appl., 69 pp.
CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 602524	A1	19940622	EP 1993-119783	19931208
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
FI 9305579	A	19940616	FI 1993-5579	19931213
CA 2111384	AA	19940616	CA 1993-2111384	19931214
JP 06209798	A2	19940802	JP 1993-342076	19931214
PRIORITY APPLN. INFO.:			DE 1992-4242202 A	19921215

GI



I

AB Acridinium compds. (I; R1 = H, hydrocarbyl; R2, R3 = H, alkyl, amino, alkoxy, cyano, carboxy, nitro, halo; R4 = nucleotide-attaching sulfonamido group; A- = anion, such as SO3F-, F3CCO2-) are obtained for chemiluminescence labeling of oligonucleotides in immunoassay. Thus, benzyl 4-(N-phenylsulfonamido)benzoate was condensed with 9-acridinecarboxylic acid chloride hydrochloride to give an acridinecarboxamide, which was debenzylated with HBr and the resulting acid hydrobromide was esterified with N-hydroxysuccinimide. The ensuing succinimidyloxy ester could then be converted to the trifluoroacetate or fluorosulfate salt for use as a label.

IT **160680-12-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; acridinium probes for chemiluminescent labeling of oligonucleotides)

RN 160680-12-6 HCAPLUS

CN Benzenepropanoic acid, 4-[[(9-acridinylcarbonyl)[4-[2-[2-(2-ethoxyethoxy)ethoxy]ethoxy]phenyl]amino]sulfonyl]-, monohydrobromide (9CI) (CA INDEX NAME)




```
=> d his

     (FILE 'HOME' ENTERED AT 01:59:00 ON 06 FEB 2006)

     FILE 'REGISTRY' ENTERED AT 01:59:12 ON 06 FEB 2006
L1              STRUCTURE UPLOADED
L2            0 S L1
L3            8 S L1 FULL

     FILE 'HCAPLUS' ENTERED AT 02:01:47 ON 06 FEB 2006
L4            4 S L3

=> file caold
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      25.50     193.97

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -3.00      -3.00

FILE 'CAOLD' ENTERED AT 02:02:56 ON 06 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED:  01 May 1997 (19970501/UP)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.  Title keywords, authors, patent
  assignees, and patent information, e.g., patent numbers, are
  now searchable from 1907-1966.  TIFF images of CA abstracts
  printed between 1907-1966 are available in the PAGE
  display formats.

  New CAS Information Use Policies, enter HELP USAGETERMS for details.

  This file supports REGISTRY for direct browsing and searching of
  all substance data from the REGISTRY file.  Enter HELP FIRST for
```

more information.

=> file caold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.44	194.41

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-3.00

FILE 'CAOLD' ENTERED AT 02:03:02 ON 06 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> s l3
L5 0 L3

=>